<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/VYquM9y_iteeD6MzsBQr1MQWWRt6zcx95z55fX3Z8o043EIdJzexXtnD_7br2p0Ss5KLuU89DbGwr6quAQ3HZQ=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"immunological-disorders;mast-cells;randomized-controlled-trials;skin-manifestations","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-021-01537-w"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Martin Metz","Gordon Sussman","Rémi Gagnon","Petra Staubach","Tonny Tanus","William H. Yang","Jeremy J. Lim","Holly J. Clarke","Joshua Galanter","Leslie W. Chinn","Tom Chu","Anastasia Teterina","Tracy Burgess","D. James Haddon","Timothy T. Lu","Marcus Maurer"],"publishedAt":1636329600,"publishedAtString":"2021-11-08","title":"Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Immunological disorders,Mast cells,Randomized controlled trials,Skin manifestations"},"journal":{"pcode":"nm","title":"nature medicine","volume":"27","issue":"11","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","description":"Bruton’s tyrosine kinase (BTK) is crucial for FcεRI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. This double-blind, placebo-controlled, phase 2 trial (EudraCT ID \n                2016-004624-35\n                \n              ) randomized 93 adults with antihistamine-refractory CSU to 50 mg daily, 150 mg daily and 200 mg twice daily of fenebrutinib or placebo for 8 weeks. The primary end point was change from baseline in urticaria activity score over 7 d (UAS7) at week 8. Secondary end points were the change from baseline in UAS7 at week 4 and the proportion of patients well-controlled (UAS7 ≤ 6) at week 8. Fenebrutinib efficacy in patients with type IIb autoimmunity and effects on IgG-anti-FcεRI were exploratory end points. Safety was also evaluated. The primary end point was met, with dose-dependent improvements in UAS7 at week 8 occurring at 200 mg twice daily and 150 mg daily, but not at 50 mg daily of fenebrutinib versus placebo. Asymptomatic, reversible grade 2 and 3 liver transaminase elevations occurred in the fenebrutinib 150 mg daily and 200 mg twice daily groups (2 patients each). Fenebrutinib diminished disease activity in patients with antihistamine-refractory CSU, including more patients with refractory type IIb autoimmunity. These results support the potential use of BTK inhibition in antihistamine-refractory CSU. Fenebrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduces disease activity in patients with chronic spontaneous urticaria refractory to antihistamines, suggesting that this treatment type could be an alternative to standard of care anti-IgE therapy.","datePublished":"2021-11-08T00:00:00Z","dateModified":"2021-11-08T00:00:00Z","pageStart":"1961","pageEnd":"1969","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-021-01537-w","keywords":["Immunological disorders","Mast cells","Randomized controlled trials","Skin manifestations","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig3_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"27","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Martin Metz","url":"http://orcid.org/0000-0002-4070-9976","affiliation":[{"name":"Charité-Universitätsmedizin Berlin","address":{"name":"Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP","address":{"name":"Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Gordon Sussman","affiliation":[{"name":"St. Michael’s Hospital and University of Toronto","address":{"name":"Division of Allergy and Clinical Immunology, St. Michael’s Hospital and University of Toronto, Toronto, Canada","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Rémi Gagnon","affiliation":[{"name":"Centre Hospitalier Universitaire de Québec","address":{"name":"Service d’Allergie et Immunologie, Département de Médecine, Centre Hospitalier Universitaire de Québec, Quebec City, Canada","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Petra Staubach","affiliation":[{"name":"University Medical Center Mainz","address":{"name":"Department of Dermatology, University Medical Center Mainz, Mainz, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Tonny Tanus","affiliation":[{"name":"Kern Allergy Medical Clinic Inc.","address":{"name":"Kern Allergy Medical Clinic Inc., Bakersfield, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"William H. Yang","affiliation":[{"name":"University of Ottawa","address":{"name":"Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, Canada","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jeremy J. Lim","affiliation":[{"name":"Genentech, Inc.","address":{"name":"Genentech, Inc., South San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Holly J. Clarke","affiliation":[{"name":"Genentech, Inc.","address":{"name":"Genentech, Inc., South San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Joshua Galanter","affiliation":[{"name":"Genentech, Inc.","address":{"name":"Genentech, Inc., South San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Leslie W. Chinn","affiliation":[{"name":"Genentech, Inc.","address":{"name":"Genentech, Inc., South San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Tom Chu","affiliation":[{"name":"Genentech, Inc.","address":{"name":"Genentech, Inc., South San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Anastasia Teterina","affiliation":[{"name":"Hoffman-LaRoche Limited","address":{"name":"Hoffman-LaRoche Limited, Missisauga, Canada","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Tracy Burgess","affiliation":[{"name":"Genentech, Inc.","address":{"name":"Genentech, Inc., South San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"D. James Haddon","affiliation":[{"name":"Genentech, Inc.","address":{"name":"Genentech, Inc., South San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Timothy T. Lu","affiliation":[{"name":"Genentech, Inc.","address":{"name":"Genentech, Inc., South San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Marcus Maurer","url":"http://orcid.org/0000-0002-4121-481X","affiliation":[{"name":"Charité-Universitätsmedizin Berlin","address":{"name":"Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP","address":{"name":"Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany","@type":"PostalAddress"},"@type":"Organization"}],"email":"marcus.maurer@charite.de","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-021-01537-w">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial">
    <meta name="dc.source" content="Nature Medicine 2021 27:11">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2021-11-08">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2021 The Author(s)">
    <meta name="dc.rights" content="2021 The Author(s)">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="Bruton’s tyrosine kinase (BTK) is crucial for FcεRI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. This double-blind, placebo-controlled, phase 2 trial (EudraCT ID 2016-004624-35 ) randomized 93 adults with antihistamine-refractory CSU to 50 mg daily, 150 mg daily and 200 mg twice daily of fenebrutinib or placebo for 8 weeks. The primary end point was change from baseline in urticaria activity score over 7 d (UAS7) at week 8. Secondary end points were the change from baseline in UAS7 at week 4 and the proportion of patients well-controlled (UAS7 ≤ 6) at week 8. Fenebrutinib efficacy in patients with type IIb autoimmunity and effects on IgG-anti-FcεRI were exploratory end points. Safety was also evaluated. The primary end point was met, with dose-dependent improvements in UAS7 at week 8 occurring at 200 mg twice daily and 150 mg daily, but not at 50 mg daily of fenebrutinib versus placebo. Asymptomatic, reversible grade 2 and 3 liver transaminase elevations occurred in the fenebrutinib 150 mg daily and 200 mg twice daily groups (2 patients each). Fenebrutinib diminished disease activity in patients with antihistamine-refractory CSU, including more patients with refractory type IIb autoimmunity. These results support the potential use of BTK inhibition in antihistamine-refractory CSU. Fenebrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduces disease activity in patients with chronic spontaneous urticaria refractory to antihistamines, suggesting that this treatment type could be an alternative to standard of care anti-IgE therapy.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2021-11-08">
    <meta name="prism.volume" content="27">
    <meta name="prism.number" content="11">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="1961">
    <meta name="prism.endingPage" content="1969">
    <meta name="prism.copyright" content="2021 The Author(s)">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-021-01537-w">
    <meta name="prism.doi" content="doi:10.1038/s41591-021-01537-w">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-021-01537-w.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-021-01537-w">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial">
    <meta name="citation_volume" content="27">
    <meta name="citation_issue" content="11">
    <meta name="citation_publication_date" content="2021/11">
    <meta name="citation_online_date" content="2021/11/08">
    <meta name="citation_firstpage" content="1961">
    <meta name="citation_lastpage" content="1969">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-021-01537-w">
    <meta name="DOI" content="10.1038/s41591-021-01537-w">
    <meta name="size" content="240409">
    <meta name="citation_doi" content="10.1038/s41591-021-01537-w">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-021-01537-w&amp;api_key=">
    <meta name="description" content="Bruton’s tyrosine kinase (BTK) is crucial for FcεRI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. This double-blind, placebo-controlled, phase 2 trial (EudraCT ID 2016-004624-35 ) randomized 93 adults with antihistamine-refractory CSU to 50 mg daily, 150 mg daily and 200 mg twice daily of fenebrutinib or placebo for 8 weeks. The primary end point was change from baseline in urticaria activity score over 7 d (UAS7) at week 8. Secondary end points were the change from baseline in UAS7 at week 4 and the proportion of patients well-controlled (UAS7 ≤ 6) at week 8. Fenebrutinib efficacy in patients with type IIb autoimmunity and effects on IgG-anti-FcεRI were exploratory end points. Safety was also evaluated. The primary end point was met, with dose-dependent improvements in UAS7 at week 8 occurring at 200 mg twice daily and 150 mg daily, but not at 50 mg daily of fenebrutinib versus placebo. Asymptomatic, reversible grade 2 and 3 liver transaminase elevations occurred in the fenebrutinib 150 mg daily and 200 mg twice daily groups (2 patients each). Fenebrutinib diminished disease activity in patients with antihistamine-refractory CSU, including more patients with refractory type IIb autoimmunity. These results support the potential use of BTK inhibition in antihistamine-refractory CSU. Fenebrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduces disease activity in patients with chronic spontaneous urticaria refractory to antihistamines, suggesting that this treatment type could be an alternative to standard of care anti-IgE therapy.">
    <meta name="dc.creator" content="Metz, Martin">
    <meta name="dc.creator" content="Sussman, Gordon">
    <meta name="dc.creator" content="Gagnon, Rémi">
    <meta name="dc.creator" content="Staubach, Petra">
    <meta name="dc.creator" content="Tanus, Tonny">
    <meta name="dc.creator" content="Yang, William H.">
    <meta name="dc.creator" content="Lim, Jeremy J.">
    <meta name="dc.creator" content="Clarke, Holly J.">
    <meta name="dc.creator" content="Galanter, Joshua">
    <meta name="dc.creator" content="Chinn, Leslie W.">
    <meta name="dc.creator" content="Chu, Tom">
    <meta name="dc.creator" content="Teterina, Anastasia">
    <meta name="dc.creator" content="Burgess, Tracy">
    <meta name="dc.creator" content="Haddon, D. James">
    <meta name="dc.creator" content="Lu, Timothy T.">
    <meta name="dc.creator" content="Maurer, Marcus">
    <meta name="dc.subject" content="Immunological disorders">
    <meta name="dc.subject" content="Mast cells">
    <meta name="dc.subject" content="Randomized controlled trials">
    <meta name="dc.subject" content="Skin manifestations">
    <meta name="citation_reference" content="citation_journal_title=Allergy; citation_title=The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria; citation_author=T Zuberbier; citation_volume=73; citation_publication_date=2018; citation_pages=1393-1414; citation_doi=10.1111/all.13397; citation_id=CR1">
    <meta name="citation_reference" content="citation_journal_title=Allergy; citation_title=Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis; citation_author=J Fricke; citation_volume=75; citation_publication_date=2020; citation_pages=423-432; citation_doi=10.1111/all.14037; citation_id=CR2">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Autoimmune chronic spontaneous urticaria: what we know and what we do not know; citation_author=P Kolkhir; citation_volume=139; citation_publication_date=2017; citation_pages=1772-1781.e1; citation_doi=10.1016/j.jaci.2016.08.050; citation_id=CR3">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria; citation_author=O Schmetzer; citation_volume=142; citation_publication_date=2018; citation_pages=876-882; citation_doi=10.1016/j.jaci.2017.10.035; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=Exp. Ther. Med.; citation_title=Association of positive and negative autologous serum skin test responses with clinical features of chronic spontaneous urticaria in Asian patients: a systematic review and meta-analysis; citation_author=XL Niu; citation_volume=17; citation_publication_date=2019; citation_pages=2603-2613; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=Allergy Asthma Immunol. Res.; citation_title=Total IgE as a marker for chronic spontaneous urticaria; citation_author=S Altrichter; citation_volume=13; citation_publication_date=2021; citation_pages=206-218; citation_doi=10.4168/aair.2021.13.2.206; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=PLoS ONE; citation_title=IgE mediated autoallergy against thyroid peroxidase––a novel pathomechanism of chronic spontaneous urticaria?; citation_author=S Altrichter; citation_volume=6; citation_publication_date=2011; citation_pages=e14794; citation_doi=10.1371/journal.pone.0014794; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase; citation_author=M Maurer; citation_volume=128; citation_publication_date=2011; citation_pages=202-209.e5; citation_doi=10.1016/j.jaci.2011.04.038; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=Theranostics; citation_title=On the lipophilic nature of autoreactive IgE in chronic spontaneous urticaria; citation_author=E Lakin, MK Church, M Maurer, O Schmetzer; citation_volume=9; citation_publication_date=2019; citation_pages=829-836; citation_doi=10.7150/thno.29902; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=Clin. Exp. Immunol.; citation_title=Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria; citation_author=R Asero; citation_volume=200; citation_publication_date=2020; citation_pages=242-249; citation_doi=10.1111/cei.13428; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria; citation_author=M Hide; citation_volume=328; citation_publication_date=1993; citation_pages=1599-1604; citation_doi=10.1056/NEJM199306033282204; citation_id=CR11">
    <meta name="citation_reference" content="citation_journal_title=Allergy Asthma Immunol. Res.; citation_title=Causal relationship between anti-TPO IgE and chronic urticaria by in vitro and in vivo tests; citation_author=J Sánchez, A Sánchez, R Cardona; citation_volume=11; citation_publication_date=2019; citation_pages=29-42; citation_doi=10.4168/aair.2019.11.1.29; citation_id=CR12">
    <meta name="citation_reference" content="citation_journal_title=J. Invest. Dermatol.; citation_title=Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes; citation_author=BL Gruber, ML Baeza, MJ Marchese, V Agnello, AP Kaplan; citation_volume=90; citation_publication_date=1988; citation_pages=213-217; citation_doi=10.1111/1523-1747.ep12462239; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=Clin. Exp. Allergy; citation_title=Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria; citation_author=CE Grattan, DM Francis, M Hide, MW Greaves; citation_volume=21; citation_publication_date=1991; citation_pages=695-704; citation_doi=10.1111/j.1365-2222.1991.tb03198.x; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=J. Invest. Dermatol.; citation_title=Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria; citation_author=N Niimi; citation_volume=106; citation_publication_date=1996; citation_pages=1001-1006; citation_doi=10.1111/1523-1747.ep12338544; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Mechanism of autoimmune activation of basophils in chronic urticaria; citation_author=Y Kikuchi, AP Kaplan; citation_volume=107; citation_publication_date=2001; citation_pages=1056-1062; citation_doi=10.1067/mai.2001.115484; citation_id=CR16">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria; citation_author=Y Kikuchi, AP Kaplan; citation_volume=109; citation_publication_date=2002; citation_pages=114-118; citation_doi=10.1067/mai.2002.120954; citation_id=CR17">
    <meta name="citation_reference" content="citation_journal_title=Allergy Asthma Immunol. Res.; citation_title=Chronic spontaneous urticaria: pathogenesis and treatment considerations; citation_author=AP Kaplan; citation_volume=9; citation_publication_date=2017; citation_pages=477-482; citation_doi=10.4168/aair.2017.9.6.477; citation_id=CR18">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria; citation_author=A Kaplan; citation_volume=137; citation_publication_date=2016; citation_pages=474-481; citation_doi=10.1016/j.jaci.2015.08.023; citation_id=CR19">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Ligelizumab for chronic spontaneous urticaria; citation_author=M Maurer; citation_volume=381; citation_publication_date=2019; citation_pages=1321-1332; citation_doi=10.1056/NEJMoa1900408; citation_id=CR20">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria; citation_author=B Zweiman, M Valenzano, PC Atkins, T Tanus, JA Getsy; citation_volume=98; citation_publication_date=1996; citation_pages=89-98; citation_doi=10.1016/S0091-6749(96)70230-0; citation_id=CR21">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Classification of anti-FcϵRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity; citation_author=RA Sabroe; citation_volume=110; citation_publication_date=2002; citation_pages=492-499; citation_doi=10.1067/mai.2002.126782; citation_id=CR22">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Clinical utility of the chronic urticaria index; citation_author=MJ Biagtan, RK Viswanathan, MD Evans, SK Mathur; citation_volume=127; citation_publication_date=2011; citation_pages=1626-1627; citation_doi=10.1016/j.jaci.2011.01.045; citation_id=CR23">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria; citation_author=J Gericke; citation_volume=139; citation_publication_date=2017; citation_pages=1059-1061.e1; citation_doi=10.1016/j.jaci.2016.07.047; citation_id=CR24">
    <meta name="citation_reference" content="citation_journal_title=Br. J. Dermatol.; citation_title=Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients; citation_author=MN Ghazanfar, C Sand, SF Thomsen; citation_volume=175; citation_publication_date=2016; citation_pages=404-406; citation_doi=10.1111/bjd.14540; citation_id=CR25">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Reply; citation_author=P Kolkhir; citation_volume=141; citation_publication_date=2018; citation_pages=1166-1167; citation_doi=10.1016/j.jaci.2017.09.010; citation_id=CR26">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Detection of basophil-activating IgG autoantibodies in chronic idiopathic urticaria by induction of CD 63; citation_author=A De Swerdt; citation_volume=116; citation_publication_date=2005; citation_pages=662-667; citation_doi=10.1016/j.jaci.2005.04.042; citation_id=CR27">
    <meta name="citation_reference" content="citation_journal_title=Ann. Allergy Asthma Immunol.; citation_title=Autoantibodies in chronic idiopathic urticaria and nonurticarial systemic autoimmune disorders; citation_author=CB Cho; citation_volume=110; citation_publication_date=2013; citation_pages=29-33; citation_doi=10.1016/j.anai.2012.10.020; citation_id=CR28">
    <meta name="citation_reference" content="citation_journal_title=J. Exp. Med.; citation_title=Involvement of Bruton’s tyrosine kinase in FcεRI-dependent mast cell degranulation and cytokine production; citation_author=D Hata; citation_volume=187; citation_publication_date=1998; citation_pages=1235-1247; citation_doi=10.1084/jem.187.8.1235; citation_id=CR29">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils; citation_author=M Kneidinger; citation_volume=111; citation_publication_date=2008; citation_pages=3097-3107; citation_doi=10.1182/blood-2007-08-104372; citation_id=CR30">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity; citation_author=JA Regan; citation_volume=140; citation_publication_date=2017; citation_pages=875-879.e1; citation_doi=10.1016/j.jaci.2017.03.013; citation_id=CR31">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy; citation_author=MC Dispenza; citation_volume=141; citation_publication_date=2018; citation_pages=1914-1916.e7; citation_doi=10.1016/j.jaci.2017.12.987; citation_id=CR32">
    <meta name="citation_reference" content="citation_journal_title=Clin. Pharmacol. Ther.; citation_title=Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton’s tyrosine kinase inhibitor; citation_author=AE Herman; citation_volume=103; citation_publication_date=2018; citation_pages=1020-1028; citation_doi=10.1002/cpt.1056; citation_id=CR33">
    <meta name="citation_reference" content="Isenberg, D. et al. Efficacy, safety, and pharmacodynamic effects of Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 
                  https://doi.org/10.1002/art.41811
                  
                 (2021).">
    <meta name="citation_reference" content="citation_journal_title=Arthritis Rheumatol.; citation_title=Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study); citation_author=S Cohen; citation_volume=72; citation_publication_date=2020; citation_pages=1435-1446; citation_doi=10.1002/art.41275; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=Allergy; citation_title=The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change; citation_author=R Ertas, K Ozyurt, M Atasoy, T Hawro, M Maurer; citation_volume=73; citation_publication_date=2018; citation_pages=705-712; citation_doi=10.1111/all.13345; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria; citation_author=S Soundararajan, Y Kikuchi, K Joseph, AP Kaplan; citation_volume=115; citation_publication_date=2005; citation_pages=815-821; citation_doi=10.1016/j.jaci.2004.12.1120; citation_id=CR37">
    <meta name="citation_reference" content="Guidance for industry. Drug-induced Liver Injury: Premarketing Clinical Evaluation. Drug Safety (U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, 2009); 
                  https://www.fda.gov/media/116737/download
                  
                ">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Invest.; citation_title=Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis; citation_author=MC Dispenza; citation_volume=130; citation_publication_date=2020; citation_pages=4759-4770; citation_doi=10.1172/JCI138448; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=J. Med. Chem.; citation_title=Discovery of GDC-0853: a potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development; citation_author=JJ Crawford; citation_volume=61; citation_publication_date=2018; citation_pages=2227-2245; citation_doi=10.1021/acs.jmedchem.7b01712; citation_id=CR40">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol. Pract.; citation_title=Relevance of the basophil high-affinity IgE receptor in chronic urticaria: clinical experience from a tertiary care institution; citation_author=G Deza; citation_volume=7; citation_publication_date=2019; citation_pages=1619-1626.e1; citation_doi=10.1016/j.jaip.2019.01.026; citation_id=CR41">
    <meta name="citation_reference" content="citation_journal_title=Immunol. Rev.; citation_title=Insights into immunoglobulin E receptor signaling from structurally defined ligands; citation_author=D Holowka, D Sil, C Torigoe, B Baird; citation_volume=217; citation_publication_date=2007; citation_pages=269-279; citation_doi=10.1111/j.1600-065X.2007.00517.x; citation_id=CR42">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Syk-deficient basophils from donors with chronic idiopathic urticaria exhibit a spectrum of releasability; citation_author=BM Vonakis, SS Saini; citation_volume=121; citation_publication_date=2008; citation_pages=262-264; citation_doi=10.1016/j.jaci.2007.10.010; citation_id=CR43">
    <meta name="citation_reference" content="citation_journal_title=Clin. Exp. Allergy; citation_title=In chronic idiopathic urticaria autoantibodies against FcɛRII/CD23 induce histamine release via eosinophil activation; citation_author=A Puccetti; citation_volume=35; citation_publication_date=2005; citation_pages=1599-1607; citation_doi=10.1111/j.1365-2222.2005.02380.x; citation_id=CR44">
    <meta name="citation_reference" content="citation_journal_title=J. Immunol.; citation_title=CD23-bound IgE augments and dominates recall responses through human naive B cells; citation_author=QK Griffith, Y Liang, DO Onguru, PN Mwinzi, LM Ganley-Leal; citation_volume=186; citation_publication_date=2011; citation_pages=1060-1067; citation_doi=10.4049/jimmunol.1002709; citation_id=CR45">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Duration of humoral immunity to common viral and vaccine antigens; citation_author=IJ Amanna, NE Carlson, MK Slifka; citation_volume=357; citation_publication_date=2007; citation_pages=1903-1915; citation_doi=10.1056/NEJMoa066092; citation_id=CR46">
    <meta name="citation_reference" content="citation_journal_title=Eur. J. Immunol.; citation_title=Limiting dilution analysis of the B cell compartment in human bone marrow; citation_author=T Hibi, HM Dosch; citation_volume=16; citation_publication_date=1986; citation_pages=139-145; citation_doi=10.1002/eji.1830160206; citation_id=CR47">
    <meta name="citation_reference" content="citation_journal_title=J. Immunol.; citation_title=Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells; citation_author=CI Smith; citation_volume=152; citation_publication_date=1994; citation_pages=557-565; citation_doi=10.4049/jimmunol.152.2.557; citation_id=CR48">
    <meta name="citation_reference" content="citation_journal_title=JCI Insight; citation_title=Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis; citation_author=A Katewa; citation_volume=2; citation_publication_date=2017; citation_pages=e90111; citation_doi=10.1172/jci.insight.90111; citation_id=CR49">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis; citation_author=X Montalban; citation_volume=380; citation_publication_date=2019; citation_pages=2406-2417; citation_doi=10.1056/NEJMoa1901981; citation_id=CR50">
    <meta name="citation_reference" content="citation_journal_title=BMC Gastroenterol.; citation_title=Zanubrutinib-induced liver injury: a case report and literature review; citation_author=E Atallah; citation_volume=21; citation_publication_date=2021; citation_pages=244; citation_doi=10.1186/s12876-021-01825-2; citation_id=CR51">
    <meta name="citation_reference" content="citation_journal_title=J. Allergy Clin. Immunol.; citation_title=Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy; citation_author=A Kaplan; citation_volume=132; citation_publication_date=2013; citation_pages=101-109; citation_doi=10.1016/j.jaci.2013.05.013; citation_id=CR52">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria; citation_author=M Maurer; citation_volume=368; citation_publication_date=2013; citation_pages=924-935; citation_doi=10.1056/NEJMoa1215372; citation_id=CR53">
    <meta name="citation_reference" content="citation_journal_title=J. Invest. Dermatol.; citation_title=Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study; citation_author=SS Saini; citation_volume=135; citation_publication_date=2015; citation_pages=67-75; citation_doi=10.1038/jid.2014.306; citation_id=CR54">
    <meta name="citation_reference" content="citation_journal_title=Health Qual. Life Outcomes; citation_title=Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT); citation_author=K Kulthanan; citation_volume=14; citation_publication_date=2016; citation_pages=61; citation_doi=10.1186/s12955-016-0466-y; citation_id=CR55">
    <meta name="citation_reference" content="citation_journal_title=Ann. Allergy Asthma Immunol.; citation_title=Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria; citation_author=SD Mathias, RD Crosby, JL Zazzali, M Maurer, SS Saini; citation_volume=108; citation_publication_date=2012; citation_pages=20-24; citation_doi=10.1016/j.anai.2011.09.008; citation_id=CR56">
    <meta name="citation_reference" content="citation_title=Clinical Trials with Missing Data: a Guide for Practitioners; citation_publication_date=2014; citation_id=CR57; citation_author=M O’Kelly; citation_author=B Ratitch; citation_publisher=John Wiley &amp; Sons">
    <meta name="citation_author" content="Metz, Martin">
    <meta name="citation_author_institution" content="Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany">
    <meta name="citation_author_institution" content="Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany">
    <meta name="citation_author" content="Sussman, Gordon">
    <meta name="citation_author_institution" content="Division of Allergy and Clinical Immunology, St. Michael’s Hospital and University of Toronto, Toronto, Canada">
    <meta name="citation_author" content="Gagnon, Rémi">
    <meta name="citation_author_institution" content="Service d’Allergie et Immunologie, Département de Médecine, Centre Hospitalier Universitaire de Québec, Quebec City, Canada">
    <meta name="citation_author" content="Staubach, Petra">
    <meta name="citation_author_institution" content="Department of Dermatology, University Medical Center Mainz, Mainz, Germany">
    <meta name="citation_author" content="Tanus, Tonny">
    <meta name="citation_author_institution" content="Kern Allergy Medical Clinic Inc., Bakersfield, USA">
    <meta name="citation_author" content="Yang, William H.">
    <meta name="citation_author_institution" content="Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, Canada">
    <meta name="citation_author" content="Lim, Jeremy J.">
    <meta name="citation_author_institution" content="Genentech, Inc., South San Francisco, USA">
    <meta name="citation_author" content="Clarke, Holly J.">
    <meta name="citation_author_institution" content="Genentech, Inc., South San Francisco, USA">
    <meta name="citation_author" content="Galanter, Joshua">
    <meta name="citation_author_institution" content="Genentech, Inc., South San Francisco, USA">
    <meta name="citation_author" content="Chinn, Leslie W.">
    <meta name="citation_author_institution" content="Genentech, Inc., South San Francisco, USA">
    <meta name="citation_author" content="Chu, Tom">
    <meta name="citation_author_institution" content="Genentech, Inc., South San Francisco, USA">
    <meta name="citation_author" content="Teterina, Anastasia">
    <meta name="citation_author_institution" content="Hoffman-LaRoche Limited, Missisauga, Canada">
    <meta name="citation_author" content="Burgess, Tracy">
    <meta name="citation_author_institution" content="Genentech, Inc., South San Francisco, USA">
    <meta name="citation_author" content="Haddon, D. James">
    <meta name="citation_author_institution" content="Genentech, Inc., South San Francisco, USA">
    <meta name="citation_author" content="Lu, Timothy T.">
    <meta name="citation_author_institution" content="Genentech, Inc., South San Francisco, USA">
    <meta name="citation_author" content="Maurer, Marcus">
    <meta name="citation_author_institution" content="Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany">
    <meta name="citation_author_institution" content="Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial">
    <meta name="twitter:description" content="Nature Medicine - Fenebrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduces disease activity in patients with chronic spontaneous urticaria refractory to antihistamines, suggesting...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-021-01537-w">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial - Nature Medicine">
    <meta property="og:description" content="Fenebrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduces disease activity in patients with chronic spontaneous urticaria refractory to antihistamines, suggesting that this treatment type could be an alternative to standard of care anti-IgE therapy.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,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");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script></head>
<body class="article-page"><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-021-01537-w;doi=10.1038/s41591-021-01537-w;subjmeta=1630,1807,1812,223,249,250,2504,2779,308,631,692,699,777;kwrd=Immunological+disorders,Mast+cells,Randomized+controlled+trials,Skin+manifestations">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-786839217&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-021-01537-w%26doi%3D10.1038/s41591-021-01537-w%26subjmeta%3D1630,1807,1812,223,249,250,2504,2779,308,631,692,699,777%26kwrd%3DImmunological+disorders,Mast+cells,Randomized+controlled+trials,Skin+manifestations">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-786839217&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-021-01537-w%26doi%3D10.1038/s41591-021-01537-w%26subjmeta%3D1630,1807,1812,223,249,250,2504,2779,308,631,692,699,777%26kwrd%3DImmunological+disorders,Mast+cells,Randomized+controlled+trials,Skin+manifestations"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-021-01537-w"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01537-w.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01537-w.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2021-11-08">08 November 2021</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial</h1>
                    <ul class="c-article-author-list c-article-author-list--short js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Martin-Metz-Aff1-Aff2" data-author-popup="auth-Martin-Metz-Aff1-Aff2" data-author-search="Metz, Martin" data-track-context="researcher popup with no profile" data-track-index="1_16">Martin Metz</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-4070-9976"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-4070-9976</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Gordon-Sussman-Aff3" data-author-popup="auth-Gordon-Sussman-Aff3" data-author-search="Sussman, Gordon" data-track-context="researcher popup with no profile" data-track-index="2_16">Gordon Sussman</a><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-R_mi-Gagnon-Aff4" data-author-popup="auth-R_mi-Gagnon-Aff4" data-author-search="Gagnon, Rémi" data-track-context="researcher popup with no profile" data-track-index="3_16">Rémi Gagnon</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Petra-Staubach-Aff5" data-author-popup="auth-Petra-Staubach-Aff5" data-author-search="Staubach, Petra" data-track-context="researcher popup with no profile" data-track-index="4_16">Petra Staubach</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Tonny-Tanus-Aff6" data-author-popup="auth-Tonny-Tanus-Aff6" data-author-search="Tanus, Tonny" data-track-context="researcher popup with no profile" data-track-index="5_16">Tonny Tanus</a><sup class="u-js-hide"><a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-William_H_-Yang-Aff7" data-author-popup="auth-William_H_-Yang-Aff7" data-author-search="Yang, William H." data-track-context="researcher popup with no profile" data-track-index="6_16">William H. Yang</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jeremy_J_-Lim-Aff8" data-author-popup="auth-Jeremy_J_-Lim-Aff8" data-author-search="Lim, Jeremy J." data-track-context="researcher popup with no profile" data-track-index="7_16">Jeremy J. Lim</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Holly_J_-Clarke-Aff8" data-author-popup="auth-Holly_J_-Clarke-Aff8" data-author-search="Clarke, Holly J." data-track-context="researcher popup with no profile" data-track-index="8_16">Holly J. Clarke</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Joshua-Galanter-Aff8" data-author-popup="auth-Joshua-Galanter-Aff8" data-author-search="Galanter, Joshua" data-track-context="researcher popup with no profile" data-track-index="9_16">Joshua Galanter</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Leslie_W_-Chinn-Aff8" data-author-popup="auth-Leslie_W_-Chinn-Aff8" data-author-search="Chinn, Leslie W." data-track-context="researcher popup with no profile" data-track-index="10_16">Leslie W. Chinn</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Tom-Chu-Aff8" data-author-popup="auth-Tom-Chu-Aff8" data-author-search="Chu, Tom" data-track-context="researcher popup with no profile" data-track-index="11_16">Tom Chu</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Anastasia-Teterina-Aff9" data-author-popup="auth-Anastasia-Teterina-Aff9" data-author-search="Teterina, Anastasia" data-track-context="researcher popup with no profile" data-track-index="12_16">Anastasia Teterina</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Tracy-Burgess-Aff8" data-author-popup="auth-Tracy-Burgess-Aff8" data-author-search="Burgess, Tracy" data-track-context="researcher popup with no profile" data-track-index="13_16">Tracy Burgess</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-D__James-Haddon-Aff8" data-author-popup="auth-D__James-Haddon-Aff8" data-author-search="Haddon, D. James" data-track-context="researcher popup with no profile" data-track-index="14_16">D. James Haddon</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Timothy_T_-Lu-Aff8" data-author-popup="auth-Timothy_T_-Lu-Aff8" data-author-search="Lu, Timothy T." data-track-context="researcher popup with no profile" data-track-index="15_16">Timothy T. Lu</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 16 authors for this article" title="Show all 16 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Marcus-Maurer-Aff1-Aff2" data-author-popup="auth-Marcus-Maurer-Aff1-Aff2" data-author-search="Maurer, Marcus" data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="16_16">Marcus Maurer<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-4121-481X"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-4121-481X</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;27</b>,&nbsp;<span class="u-visually-hidden">pages </span>1961–1969 (<span data-test="article-publication-year">2021</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">17k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">85 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">20 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-021-01537-w/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    

    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Bruton’s tyrosine kinase (BTK) is crucial for FcεRI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. This double-blind, placebo-controlled, phase 2 trial (EudraCT ID <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004624-35">2016-004624-35</a>) randomized 93 adults with antihistamine-refractory CSU to 50 mg daily, 150 mg daily and 200 mg twice daily of fenebrutinib or placebo for 8 weeks. The primary end point was change from baseline in urticaria activity score over 7 d (UAS7) at week 8. Secondary end points were the change from baseline in UAS7 at week 4 and the proportion of patients well-controlled (UAS7 ≤ 6) at week 8. Fenebrutinib efficacy in patients with type IIb autoimmunity and effects on IgG-anti-FcεRI were exploratory end points. Safety was also evaluated. The primary end point was met, with dose-dependent improvements in UAS7 at week 8 occurring at 200 mg twice daily and 150 mg daily, but not at 50 mg daily of fenebrutinib versus placebo. Asymptomatic, reversible grade 2 and 3 liver transaminase elevations occurred in the fenebrutinib 150 mg daily and 200 mg twice daily groups (2 patients each). Fenebrutinib diminished disease activity in patients with antihistamine-refractory CSU, including more patients with refractory type IIb autoimmunity. These results support the potential use of BTK inhibition in antihistamine-refractory CSU.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41598-025-94841-1/MediaObjects/41598_2025_94841_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41598-025-94841-1?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41598-025-94841-1">Serum MRGPRX2 and substance P levels are biomarkers of disease activity rather than an antihistamine response in chronic spontaneous urticaria
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">23 March 2025</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41572-022-00389-z/MediaObjects/41572_2022_389_Fig2_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41572-022-00389-z?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41572-022-00389-z">Urticaria
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                        
                                         <span class="c-article-meta-recommendations__date">15 September 2022</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-024-03009-3/MediaObjects/41591_2024_3009_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41591-024-03009-3?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s41591-024-03009-3">CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">05 June 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749524656,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>CSU is characterized by the development of wheals, angioedema or both for more than six weeks without an obvious external cause. Approximately 1% of the population is affected (point prevalence = 0.7%; lifetime prevalence = 1.4%); in most patients, the disease considerably impairs quality of life<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Zuberbier, T. et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73, 1393–1414 (2018)." href="/articles/s41591-021-01537-w#ref-CR1" id="ref-link-section-d72534159e667">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Fricke, J. et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy 75, 423–432 (2020)." href="/articles/s41591-021-01537-w#ref-CR2" id="ref-link-section-d72534159e670">2</a></sup>.</p><p>CSU pathogenesis is not yet fully understood but autoallergic and autoimmune mechanisms are believed to be involved<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Kolkhir, P. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J. Allergy Clin. Immunol. 139, 1772–1781.e1 (2017)." href="#ref-CR3" id="ref-link-section-d72534159e677">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Schmetzer, O. et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J. Allergy Clin. Immunol. 142, 876–882 (2018)." href="#ref-CR4" id="ref-link-section-d72534159e677_1">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Niu, X. L. et al. Association of positive and negative autologous serum skin test responses with clinical features of chronic spontaneous urticaria in Asian patients: a systematic review and meta-analysis. Exp. Ther. Med. 17, 2603–2613 (2019)." href="#ref-CR5" id="ref-link-section-d72534159e677_2">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Altrichter, S. et al. Total IgE as a marker for chronic spontaneous urticaria. Allergy Asthma Immunol. Res. 13, 206–218 (2021)." href="/articles/s41591-021-01537-w#ref-CR6" id="ref-link-section-d72534159e680">6</a></sup>. A large proportion of patients have autoallergic CSU, also known as type I autoimmune CSU, where IgE autoantibodies target various autoantigens, for example, thyroid peroxidase<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Altrichter, S. et al. IgE mediated autoallergy against thyroid peroxidase––a novel pathomechanism of chronic spontaneous urticaria? PLoS ONE 6, e14794 (2011)." href="/articles/s41591-021-01537-w#ref-CR7" id="ref-link-section-d72534159e684">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Maurer, M. et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J. Allergy Clin. Immunol. 128, 202–209.e5 (2011)." href="/articles/s41591-021-01537-w#ref-CR8" id="ref-link-section-d72534159e687">8</a></sup> and interleukin-24<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Niu, X. L. et al. Association of positive and negative autologous serum skin test responses with clinical features of chronic spontaneous urticaria in Asian patients: a systematic review and meta-analysis. Exp. Ther. Med. 17, 2603–2613 (2019)." href="/articles/s41591-021-01537-w#ref-CR5" id="ref-link-section-d72534159e691">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Lakin, E., Church, M. K., Maurer, M. &amp; Schmetzer, O. On the lipophilic nature of autoreactive IgE in chronic spontaneous urticaria. Theranostics 9, 829–836 (2019)." href="/articles/s41591-021-01537-w#ref-CR9" id="ref-link-section-d72534159e694">9</a></sup>. Other patients have type IIb autoimmune CSU, where IgG autoantibodies target IgE or the high-affinity IgE receptor, FcεRI<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Kolkhir, P. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J. Allergy Clin. Immunol. 139, 1772–1781.e1 (2017)." href="/articles/s41591-021-01537-w#ref-CR3" id="ref-link-section-d72534159e698">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Asero, R. et al. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. Clin. Exp. Immunol. 200, 242–249 (2020)." href="/articles/s41591-021-01537-w#ref-CR10" id="ref-link-section-d72534159e701">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Hide, M. et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N. Engl. J. Med. 328, 1599–1604 (1993)." href="/articles/s41591-021-01537-w#ref-CR11" id="ref-link-section-d72534159e704">11</a></sup>. These autoantibodies activate mast cells and basophils via FcεRI receptors<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Schmetzer, O. et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J. Allergy Clin. Immunol. 142, 876–882 (2018)." href="/articles/s41591-021-01537-w#ref-CR4" id="ref-link-section-d72534159e708">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hide, M. et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N. Engl. J. Med. 328, 1599–1604 (1993)." href="#ref-CR11" id="ref-link-section-d72534159e711">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Sánchez, J., Sánchez, A. &amp; Cardona, R. Causal relationship between anti-TPO IgE and chronic urticaria by in vitro and in vivo tests. Allergy Asthma Immunol. Res. 11, 29–42 (2019)." href="#ref-CR12" id="ref-link-section-d72534159e711_1">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Gruber, B. L., Baeza, M. L., Marchese, M. J., Agnello, V. &amp; Kaplan, A. P. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J. Invest. Dermatol. 90, 213–217 (1988)." href="#ref-CR13" id="ref-link-section-d72534159e711_2">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Grattan, C. E., Francis, D. M., Hide, M. &amp; Greaves, M. W. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin. Exp. Allergy 21, 695–704 (1991)." href="#ref-CR14" id="ref-link-section-d72534159e711_3">14</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Niimi, N. et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J. Invest. Dermatol. 106, 1001–1006 (1996)." href="/articles/s41591-021-01537-w#ref-CR15" id="ref-link-section-d72534159e714">15</a></sup>. Type IIb autoantibodies fix complement<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Kikuchi, Y. &amp; Kaplan, A. P. Mechanism of autoimmune activation of basophils in chronic urticaria. J. Allergy Clin. Immunol. 107, 1056–1062 (2001)." href="/articles/s41591-021-01537-w#ref-CR16" id="ref-link-section-d72534159e719">16</a></sup>, which augments the secretion of mast cell mediators<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Kikuchi, Y. &amp; Kaplan, A. P. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J. Allergy Clin. Immunol. 109, 114–118 (2002)." href="/articles/s41591-021-01537-w#ref-CR17" id="ref-link-section-d72534159e723">17</a></sup>.</p><p>While on current standard of care (that is, anti-IgE therapy), only 40% of patients with CSU in clinical trials achieve complete symptom control<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Kaplan, A. P. Chronic spontaneous urticaria: pathogenesis and treatment considerations. Allergy Asthma Immunol. Res. 9, 477–482 (2017)." href="/articles/s41591-021-01537-w#ref-CR18" id="ref-link-section-d72534159e730">18</a></sup>, the guideline-supported goal of urticaria treatment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Zuberbier, T. et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73, 1393–1414 (2018)." href="/articles/s41591-021-01537-w#ref-CR1" id="ref-link-section-d72534159e734">1</a></sup>. Omalizumab, a humanized anti-IgE antibody, is recommended by international guidelines as third-line treatment for patients with CSU refractory to H<sub>1</sub> antihistamines<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Zuberbier, T. et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73, 1393–1414 (2018)." href="/articles/s41591-021-01537-w#ref-CR1" id="ref-link-section-d72534159e740">1</a></sup>. After treatment with omalizumab (300 mg), 56–66% of patients with CSU were well controlled (UAS7 ≤ 6), compared to 17–25% in the placebo group<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Kaplan, A. et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J. Allergy Clin. Immunol. 137, 474–481 (2016)." href="/articles/s41591-021-01537-w#ref-CR19" id="ref-link-section-d72534159e744">19</a></sup>. More recently, ligelizumab, a high-affinity anti-IgE therapy, demonstrated efficacy in CSU<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Maurer, M. et al. Ligelizumab for chronic spontaneous urticaria. N. Engl. J. Med. 381, 1321–1332 (2019)." href="/articles/s41591-021-01537-w#ref-CR20" id="ref-link-section-d72534159e749">20</a></sup> and is currently in phase 3 clinical trials (ClinicalTrials.gov IDs: <a href="https://clinicaltrials.gov/ct2/show/NCT03580369">NCT03580369</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT03580356">NCT03580356</a>). Despite these new treatments, some patients do not respond and still need effective alternative therapy. This seems especially true for patients with type IIb autoimmunity, who tend to have increased disease activity<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Zweiman, B., Valenzano, M., Atkins, P. C., Tanus, T. &amp; Getsy, J. A. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. J. Allergy Clin. Immunol. 98, 89–98 (1996)." href="/articles/s41591-021-01537-w#ref-CR21" id="ref-link-section-d72534159e767">21</a></sup> and severity<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Sabroe, R. A. et al. Classification of anti-FcϵRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J. Allergy Clin. Immunol. 110, 492–499 (2002)." href="/articles/s41591-021-01537-w#ref-CR22" id="ref-link-section-d72534159e771">22</a></sup> and may be more refractory to current therapies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Biagtan, M. J., Viswanathan, R. K., Evans, M. D. &amp; Mathur, S. K. Clinical utility of the chronic urticaria index. J. Allergy Clin. Immunol. 127, 1626–1627 (2011)." href="#ref-CR23" id="ref-link-section-d72534159e775">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Gericke, J. et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J. Allergy Clin. Immunol. 139, 1059–1061.e1 (2017)." href="#ref-CR24" id="ref-link-section-d72534159e775_1">24</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Ghazanfar, M. N., Sand, C. &amp; Thomsen, S. F. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br. J. Dermatol. 175, 404–406 (2016)." href="/articles/s41591-021-01537-w#ref-CR25" id="ref-link-section-d72534159e778">25</a></sup>. A positive basophil histamine release assay (BHRA<sup>+</sup>) indicates the presence of functional anti-IgE and/or anti-FcεRI autoantibodies and is a marker of type IIb autoimmunity<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Kolkhir, P. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J. Allergy Clin. Immunol. 139, 1772–1781.e1 (2017)." href="/articles/s41591-021-01537-w#ref-CR3" id="ref-link-section-d72534159e785">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Kolkhir, P. et al. Reply. J. Allergy Clin. Immunol. 141, 1166–1167 (2018)." href="/articles/s41591-021-01537-w#ref-CR26" id="ref-link-section-d72534159e788">26</a></sup>. Low serum total IgE is also associated with type IIb autoimmunity<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="De Swerdt, A. et al. Detection of basophil-activating IgG autoantibodies in chronic idiopathic urticaria by induction of CD 63. J. Allergy Clin. Immunol. 116, 662–667 (2005)." href="/articles/s41591-021-01537-w#ref-CR27" id="ref-link-section-d72534159e792">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Cho, C. B. et al. Autoantibodies in chronic idiopathic urticaria and nonurticarial systemic autoimmune disorders. Ann. Allergy Asthma Immunol. 110, 29–33 (2013)." href="/articles/s41591-021-01537-w#ref-CR28" id="ref-link-section-d72534159e795">28</a></sup>.</p><p>FcεRI cross-linking rapidly activates BTK in both mast cells and basophils, the key cell types in CSU pathogenesis. BTK-null mice and patients deficient in BTK have impaired FcεRI signaling, which decreases histamine and inflammatory cytokine release by mast cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Hata, D. et al. Involvement of Bruton’s tyrosine kinase in FcεRI-dependent mast cell degranulation and cytokine production. J. Exp. Med. 187, 1235–1247 (1998)." href="/articles/s41591-021-01537-w#ref-CR29" id="ref-link-section-d72534159e802">29</a></sup> and basophils<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Kneidinger, M. et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 111, 3097–3107 (2008)." href="/articles/s41591-021-01537-w#ref-CR30" id="ref-link-section-d72534159e806">30</a></sup>. In addition, BTK inhibition with ibrutinib demonstrated a reduction in mast cell and IgE-dependent basophil reactivity in allergic patients with chronic lymphocytic leukemia and in patients with IgE-mediated allergy to peanut and/or tree nuts<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Regan, J. A. et al. Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. J. Allergy Clin. Immunol. 140, 875–879.e1 (2017)." href="/articles/s41591-021-01537-w#ref-CR31" id="ref-link-section-d72534159e810">31</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Dispenza, M. C. et al. Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy. J. Allergy Clin. Immunol. 141, 1914–1916.e7 (2018)." href="/articles/s41591-021-01537-w#ref-CR32" id="ref-link-section-d72534159e813">32</a></sup>.</p><p>Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, blocks IgE-mediated histamine release from mast cells <i>i</i>n vitro. In a recent phase 1 study, fenebrutinib inhibited IgE-mediated basophil activation in healthy volunteers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Herman, A. E. et al. Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton’s tyrosine kinase inhibitor. Clin. Pharmacol. Ther. 103, 1020–1028 (2018)." href="/articles/s41591-021-01537-w#ref-CR33" id="ref-link-section-d72534159e824">33</a></sup>. Furthermore, BTK is critical in B cells for B cell receptor (BCR) signaling, proliferation, and survival. In patients with rheumatoid arthritis and lupus, fenebrutinib caused dose-dependent reductions in rheumatoid factor and anti-double-stranded DNA autoantibodies, respectively<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Isenberg, D. et al. Efficacy, safety, and pharmacodynamic effects of Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 
                  https://doi.org/10.1002/art.41811
                  
                 (2021)." href="/articles/s41591-021-01537-w#ref-CR34" id="ref-link-section-d72534159e828">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Cohen, S. et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study). Arthritis Rheumatol. 72, 1435–1446 (2020)." href="/articles/s41591-021-01537-w#ref-CR35" id="ref-link-section-d72534159e831">35</a></sup>. Thus, BTK inhibition by fenebrutinib may also disrupt production of FcεRI-activating autoantibodies in CSU. This phase 2 study was originally designed as a pilot study to assess initial clinical efficacy of 200 mg twice daily of fenebrutinib compared to placebo in adult patients with CSU (cohort 1). Based on results from an interim analysis, the study was amended to include a dose-ranging cohort (cohort 2) to characterize the dose– and exposure–response relationships for safety and efficacy to select the optimal dose for potential further studies.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Study design and participants</h3><p>This phase 2, multicenter, randomized, double-blind, placebo-controlled, pilot (cohort 1) and dose-ranging (cohort 2) study (EudraCT ID <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004624-35">2016-004624-35</a>; ClinicalTrials.gov ID <a href="https://clinicaltrials.gov/ct2/show/NCT03137069">NCT03137069</a>) examined fenebrutinib efficacy and safety compared to placebo in adult patients who had CSU for more than six months and were symptomatic despite treatment with H<sub>1</sub> antihistamines (up to fourfold the approved dose). Both cohorts had a two-week screening period, an eight-week treatment period and a four-week follow-up period (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig4">1</a>). Cohort 2 was initiated after a prespecified interim analysis of cohort 1 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig4">1</a>). An adaptive study design was used because the study was originally designed as a pilot study and the extent of target engagement was unknown (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01537-w#Sec11">Methods</a>). This report describes the cohort 2 results with cohort 1 data in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">Supplementary Information</a>. Patients in cohort 2 were randomly allocated to placebo or fenebrutinib (50 mg or 150 mg daily or 200 mg twice daily). During the treatment period, patients maintained stable doses of H<sub>1</sub> antihistamines. The primary end point was the change from baseline in the UAS7 at week 8. Secondary end points were the change from baseline in UAS7 at week 4 and the proportion of patients well-controlled (UAS7 ≤ 6) at week 8. Additionally, we explored fenebrutinib efficacy in patients with type IIb autoimmunity and fenebrutinib effects on IgG-anti-FcεRI levels. We also monitored safety events in this patient population.</p><p>Enrollment for Cohort 2 occurred between 28 May 2018 and 1 August 2019. Ninety-three patients were randomly assigned to treatment groups; 80 patients (86%) completed the study treatment period (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig1">1</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig5">2</a>, cohort 1). There were no substantial imbalances between treatment groups with respect to baseline CSU symptoms (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab1">1</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">1</a>, cohort 1). We stopped recruitment after an interim analysis of cohort 2 because the study objectives for characterizing fenebrutinib’s efficacy, exposure and safety in patients with CSU were satisfied. We observed a trend in the exposure–efficacy relationship; a biologically relevant subpopulation demonstrated differential efficacy and we observed transient transaminase elevations in a limited number of patients.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Fig. 1"><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01537-w/figures/1" rel="nofollow"><picture><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="481"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p><b>CONSORT diagram for cohort 2.</b></p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01537-w/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Patient baseline characteristics (modified intention-to-treat population)<sup>a</sup> in cohort 2</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-021-01537-w/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec4">BTK inhibition with fenebrutinib is effective in CSU</h3><p>Compared with placebo, 150 mg daily and 200 mg twice daily of fenebrutinib resulted in greater mean reductions from baseline in the primary end point, CSU disease activity by UAS7 at week 8 (least squares mean difference versus placebo: 150 mg daily, −6.4; 200 mg twice daily, −9.5; Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab2">2</a> and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig2">2a</a>), which was consistent with changes observed in UAS7 weekly itch (least squares mean difference versus placebo: 150 mg daily, −2.3; 200 mg twice daily, −3.6; Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab2">2</a> and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig2">2b</a>) and hive scores (least squares mean difference versus placebo: 150 mg daily, −4.2; 200 mg twice daily, −6.0; Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab2">2</a> and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig2">2c</a>). Fenebrutinib treatment also led to dose-dependent increases in the proportion of patients with well-controlled disease (UAS7 ≤ 6) at week 8, a secondary end point (50 mg daily, 35%; 150 mg daily, 46%; 200 mg twice daily, 57% versus placebo, 22%; Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab2">2</a> and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig2">2d</a>), and the proportion of patients with complete response at week 8 (50 mg daily, 13%; 150 mg daily, 25%; 200 mg twice daily, 39% versus placebo, 4%; Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab2">2</a> and Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">3</a>). The cohort 1 efficacy outcomes were consistent with cohort 2 (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">2</a>).</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-2"><figure><figcaption class="c-article-table__figcaption"><b id="Tab2" data-test="table-caption">Table 2 Efficacy end points (modified intention-to-treat population) in cohort 2</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-021-01537-w/tables/2" aria-label="Full size table 2"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Effects of fenebrutinib on the UAS7, UAS7 components and proportion of well-controlled responders."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Effects of fenebrutinib on the UAS7, UAS7 components and proportion of well-controlled responders.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01537-w/figures/2" rel="nofollow"><picture><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="1790"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p><b>a</b>, Mean profile plot of change from baseline in the UAS7 by study week in the different treatment arms. <b>b</b>,<b>c</b>, Mean change from baseline in UAS7 components: weekly itch score (<b>b</b>) and weekly hive score (<b>c</b>). <b>a</b>–<b>c</b>, <i>n</i> = 23 patients for each arm at the initial time point; no imputation for missing values was performed. The center is the mean and the error bars are the s.e.m.; the blue shaded area is the follow-up period. <b>d</b>, Proportion of patients who were well-controlled responders (UAS7 ≤ 6). The complete patient numbers per arm are shown in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">1</a>.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01537-w/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec5">BTK inhibition results in rapid improvement of CSU</h3><p>Near-maximal fenebrutinib efficacy was observed early in the study, with the change from baseline in UAS7 at week 4 (secondary end point), showing a treatment effect similar to the change in the UAS7 seen at week 8 (least squares mean difference versus placebo, 200 mg twice daily (week 4, −10.8; week 8, −9.5); 150 mg daily (week 4, −5.0; week 8, −6.4); 50 mg daily (week 4, −2.8; week 8, −0.5); Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab2">2</a> and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig2">2a</a>) and dose-dependent increases in the proportions of patients with well-controlled disease and complete response at week 4 (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab2">2</a>, Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig2">2d</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig6">3</a>). Fenebrutinib reduced median times to the minimally important difference (MID) (200 mg twice daily, 1 week; 150 mg daily, 1.5 weeks; 50 mg daily, 1 week) over placebo (3 weeks) (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab2">2</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig7">4a</a>; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig7">4b</a>, cohort 1). Post-hoc analysis showed that even within the first week of treatment, fenebrutinib led to marked increases in the proportion of well-controlled patients (50 mg daily, 21.7%; 150 mg daily, 20.8%; 200 mg twice daily, 39.1%) compared with placebo (4.3%; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig2">2d</a>).</p><h3 class="c-article__sub-heading" id="Sec6">Disease reduction in patients with and without type IIb autoimmunity</h3><p>At 200 mg twice daily, fenebrutinib improved disease activity in patients with and without markers of type IIb autoimmunity at baseline (BHRA<sup>+</sup>, IgG-anti-FcεRI<sup>+</sup> and low serum IgE (&lt;43 IU ml<sup>−1</sup>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Ertas, R., Ozyurt, K., Atasoy, M., Hawro, T. &amp; Maurer, M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy 73, 705–712 (2018)." href="/articles/s41591-021-01537-w#ref-CR36" id="ref-link-section-d72534159e2616">36</a></sup>), indicated by similar UAS7 improvements for each subgroup compared to placebo (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig3">3a</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig8">5</a>). The cohort 1 patient subgroups receiving 200 mg twice daily of fenebrutinib showed similar results (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig9">6</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig10">7</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Effects of fenebrutinib on markers of type IIb autoimmunity."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Effects of fenebrutinib on markers of type IIb autoimmunity.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01537-w/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="704"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>a</b>, UAS7 values, stratified by baseline BHRA, IgG-anti-FcεRI and IgE concentrations in the placebo and fenebrutinib dose groups from baseline through week 12. Thin lines, individual patients; thick lines, means. No imputation for missing values was performed. The blue shaded area represents the follow-up period. <b>b</b>, Percentage change in IgG-anti-FcεRI at week 8. The horizontal bars represent the medians. <b>c</b>, Correlation of percentage change in IgG-anti-FcεR1 with change in UAS7 at week 8. <b>b</b>,<b>c</b>, Analyses were performed in patients who were IgG-anti-FcεRI<sup>+</sup> at baseline. The <i>ρ</i> (rho) value is based on a Spearman correlation.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01537-w/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec7">Type IIb autoimmunity and lower fenebrutinib dosing</h3><p>All fenebrutinib groups showed a greater improvement in UAS7 compared to placebo in the BHRA<sup>+</sup> subgroup (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig3">3a</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig8">5a</a>). At lower doses (50 mg, 150 mg daily), the UAS7 improved more in BHRA<sup>+</sup> patients than in BHRA<sup>−</sup> patients (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig3">3a</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig8">5</a>). Likewise, IgG-anti-FcεRI<sup>+</sup> patients showed greater efficacy at the 50 mg and 150 mg daily doses than IgG-anti-FcεRI<sup>−</sup> patients (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig3">3a</a>). Patients with low serum total IgE had a greater improvement in UAS7 relative to placebo at 50 mg daily compared to those with high serum IgE (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig3">3a</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig8">5b</a>).</p><h3 class="c-article__sub-heading" id="Sec8">BTK inhibition decreases IgG-anti-FcεRI autoantibodies</h3><p>Because fenebrutinib reduces autoantibody production in rheumatoid arthritis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Cohen, S. et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study). Arthritis Rheumatol. 72, 1435–1446 (2020)." href="/articles/s41591-021-01537-w#ref-CR35" id="ref-link-section-d72534159e2723">35</a></sup> and lupus<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Isenberg, D. et al. Efficacy, safety, and pharmacodynamic effects of Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 
                  https://doi.org/10.1002/art.41811
                  
                 (2021)." href="/articles/s41591-021-01537-w#ref-CR34" id="ref-link-section-d72534159e2727">34</a></sup>, this mechanism may also mediate efficacy in type IIb CSU. Among patients with IgG-anti-FcεRI autoantibodies, fenebrutinib substantially reduced these autoantibodies at week 8 at all dose levels compared to placebo (median percentage change from baseline: −43.7, −53.6 and −44.0% in 50 mg daily, 150 mg daily and 200 mg twice daily fenebrutinib groups, respectively; placebo, 20.4%) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig3">3b</a>). These changes were probably not due to a broader treatment effect on total antibodies; in cohort 1, compared to placebo, fenebrutinib did not cause obvious reductions in IgG subtypes (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig11">8</a>), including IgG1 and IgG3, the predominant subclasses of IgG-anti-FcεRI in CSU<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Soundararajan, S., Kikuchi, Y., Joseph, K. &amp; Kaplan, A. P. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J. Allergy Clin. Immunol. 115, 815–821 (2005)." href="/articles/s41591-021-01537-w#ref-CR37" id="ref-link-section-d72534159e2737">37</a></sup>. Greater reductions in IgG-anti-FcεRI were associated with greater decreases in UAS7 at week 8 (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig3">3c</a>).</p><h3 class="c-article__sub-heading" id="Sec9">Fenebrutinib is well-tolerated</h3><p>The most common adverse events (AEs) in cohort 2 were urticaria, nasopharyngitis and headache (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab3">3</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">3</a>), which is consistent with cohort 1 (Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">4</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">5</a>). No serious AEs (SAEs) occurred in cohort 2 (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab3">3</a>) and 2 of the 3 SAEs reported in the 200 mg twice daily fenebrutinib arm in cohort 1 were related to treatment (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">4</a>). These SAEs, periorbital cellulitis and an increase in hepatic enzymes, led to treatment withdrawal. One SAE, abdominal pain, was unrelated to the study drug and did not lead to a change in treatment. No deaths were reported in any treatment group. Severe urticaria was reported in four patients in cohort 1 after fenebrutinib treatment ceased. A similar proportion of patients in cohort 2 discontinued study treatment due to AEs in the fenebrutinib arms compared with the placebo arm (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01537-w#Tab3">3</a>). No serious, severe or opportunistic infections occurred in cohort 2. One patient in the fenebrutinib group in cohort 1 experienced sinusitis and periorbital cellulitis (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">4</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">5</a>).</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-3"><figure><figcaption class="c-article-table__figcaption"><b id="Tab3" data-test="table-caption">Table 3 AEs (safety population<sup>a</sup>) in cohort 2</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-021-01537-w/tables/3" aria-label="Full size table 3"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Grade 2 and 3 liver transaminase elevations occurred between weeks 4 and 8 in 2 patients each in the 150 mg daily and 200 mg twice daily fenebrutinib groups (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">6</a>, cohort 2). Similar elevations were seen in fenebrutinib-treated patients in cohort 1 (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">7</a>; see patient narratives in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">Supplementary Information</a>). These increases were asymptomatic and resolved 10–30 d after fenebrutinib discontinuation. Patients were asymptomatic and no cases met the Hy’s law criteria for drug-induced liver injury<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Guidance for industry. Drug-induced Liver Injury: Premarketing Clinical Evaluation. Drug Safety (U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, 2009); 
                  https://www.fda.gov/media/116737/download
                  
                " href="/articles/s41591-021-01537-w#ref-CR38" id="ref-link-section-d72534159e3592">38</a></sup>.</p><p>Compared with placebo, dose-dependent increases in mean creatinine occurred in the fenebrutinib arms starting in week 1 and continuing through week 8. No other clinically meaningful changes were observed in any other laboratory parameters.</p></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec10-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec10">Discussion</h2><div class="c-article-section__content" id="Sec10-content"><p>Selective inhibition of BTK, a key protein downstream of FcεRI and BCR signaling, with fenebrutinib resulted in clinically meaningful treatment benefit in patients with CSU refractory to antihistamines (up to fourfold the approved dose). The rapid onset of efficacy suggests that fenebrutinib’s major mechanism of action in CSU is inhibition of FcεRI signaling via BTK inhibition in mast cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Hata, D. et al. Involvement of Bruton’s tyrosine kinase in FcεRI-dependent mast cell degranulation and cytokine production. J. Exp. Med. 187, 1235–1247 (1998)." href="/articles/s41591-021-01537-w#ref-CR29" id="ref-link-section-d72534159e3608">29</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Dispenza, M. C. et al. Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. J. Clin. Invest. 130, 4759–4770 (2020)." href="/articles/s41591-021-01537-w#ref-CR39" id="ref-link-section-d72534159e3611">39</a></sup> and basophils<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Herman, A. E. et al. Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton’s tyrosine kinase inhibitor. Clin. Pharmacol. Ther. 103, 1020–1028 (2018)." href="/articles/s41591-021-01537-w#ref-CR33" id="ref-link-section-d72534159e3615">33</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Crawford, J. J. et al. Discovery of GDC-0853: a potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development. J. Med. Chem. 61, 2227–2245 (2018)." href="/articles/s41591-021-01537-w#ref-CR40" id="ref-link-section-d72534159e3618">40</a></sup>. Furthermore, the reduction of disease activity with 200 mg twice daily fenebrutinib in patients with and without type IIb autoimmunity indicates that BTK is crucial for maintaining pathology in type I and IIb autoimmune CSU.</p><p>Patients with type IIb autoimmunity experienced improvements in disease control with fenebrutinib across all doses tested. However, at lower fenebrutinib doses, patients with type IIb autoimmunity demonstrated greater benefit than patients without type IIb-associated markers. This finding suggests that patients with type IIb autoimmunity may be more sensitive to BTK inhibition, while patients with type I autoallergy may gain additional clinical benefit from higher levels of BTK inhibition to achieve maximal efficacy. The use of 50 mg daily of fenebrutinib, the lowest dose, may optimize the benefit–risk profile in BHRA<sup>+</sup> patients, given that CSU typically occurs in otherwise healthy individuals. Potential mechanisms that may contribute to the apparent greater sensitivity of patients with type IIb autoimmunity to BTK inhibition could include: lower density of surface FcεRI;<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Deza, G. et al. Relevance of the basophil high-affinity IgE receptor in chronic urticaria: clinical experience from a tertiary care institution. J. Allergy Clin. Immunol. Pract. 7, 1619–1626.e1 (2019)." href="/articles/s41591-021-01537-w#ref-CR41" id="ref-link-section-d72534159e3627">41</a></sup> weaker FcεRI activation by bivalent anti-FcεRI, relative to multivalent autoantigen–IgE complexes;<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Holowka, D., Sil, D., Torigoe, C. &amp; Baird, B. Insights into immunoglobulin E receptor signaling from structurally defined ligands. Immunol. Rev. 217, 269–279 (2007)." href="/articles/s41591-021-01537-w#ref-CR42" id="ref-link-section-d72534159e3631">42</a></sup> lower levels of Syk, a BTK-activating kinase in the FcεRI pathway;<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Vonakis, B. M. &amp; Saini, S. S. Syk-deficient basophils from donors with chronic idiopathic urticaria exhibit a spectrum of releasability. J. Allergy Clin. Immunol. 121, 262–264 (2008)." href="/articles/s41591-021-01537-w#ref-CR43" id="ref-link-section-d72534159e3635">43</a></sup> and presence of autoantibodies that activate BTK-independent pathways (for example, anti-FcεRII) in patients without type IIb autoimmunity<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Puccetti, A. et al. In chronic idiopathic urticaria autoantibodies against FcɛRII/CD23 induce histamine release via eosinophil activation. Clin. Exp. Allergy 35, 1599–1607 (2005)." href="/articles/s41591-021-01537-w#ref-CR44" id="ref-link-section-d72534159e3639">44</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="Griffith, Q. K., Liang, Y., Onguru, D. O., Mwinzi, P. N. &amp; Ganley-Leal, L. M. CD23-bound IgE augments and dominates recall responses through human naive B cells. J. Immunol. 186, 1060–1067 (2011)." href="/articles/s41591-021-01537-w#ref-CR45" id="ref-link-section-d72534159e3642">45</a></sup>.</p><p>Fenebrutinib treatment substantially reduced circulating IgG-anti-FcεRI autoantibodies at all doses tested. Greater reductions in IgG-anti-FcεRI were associated with greater decreases in disease activity, probably reflecting a reduction in autoantibody-mediated activation of mast cells and basophils in patients with type IIb autoimmunity. BTK inhibition did not appreciably affect overall serum Ig levels, which are thought to be maintained by long-lived plasma cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Amanna, I. J., Carlson, N. E. &amp; Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903–1915 (2007)." href="/articles/s41591-021-01537-w#ref-CR46" id="ref-link-section-d72534159e3649">46</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Hibi, T. &amp; Dosch, H. M. Limiting dilution analysis of the B cell compartment in human bone marrow. Eur. J. Immunol. 16, 139–145 (1986)." href="/articles/s41591-021-01537-w#ref-CR47" id="ref-link-section-d72534159e3652">47</a></sup> that downregulate <i>BTK</i> gene expression<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Smith, C. I. et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J. Immunol. 152, 557–565 (1994)." href="/articles/s41591-021-01537-w#ref-CR48" id="ref-link-section-d72534159e3659">48</a></sup>. Fenebrutinib probably reduced autoantibody production through the inhibition of BCR-mediated differentiation, activation and proliferation of self-reactive, BTK-expressing plasmablasts<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Katewa, A. et al. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis. JCI Insight 2, e90111 (2017)." href="/articles/s41591-021-01537-w#ref-CR49" id="ref-link-section-d72534159e3663">49</a></sup>. Similarly, fenebrutinib treatment of patients with rheumatoid arthritis and lupus resulted in greater proportional reductions in rheumatoid factor<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Cohen, S. et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study). Arthritis Rheumatol. 72, 1435–1446 (2020)." href="/articles/s41591-021-01537-w#ref-CR35" id="ref-link-section-d72534159e3667">35</a></sup> and anti-double-stranded DNA<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Isenberg, D. et al. Efficacy, safety, and pharmacodynamic effects of Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 
                  https://doi.org/10.1002/art.41811
                  
                 (2021)." href="/articles/s41591-021-01537-w#ref-CR34" id="ref-link-section-d72534159e3672">34</a></sup> compared to total IgM or IgG subclasses, respectively. Further studies are needed to determine whether BTK inhibition affects production of other autoantibodies in CSU and their relationship with efficacy.</p><p>Although AEs were generally well balanced and mild or moderate, more patients with CSU receiving fenebrutinib than placebo reported urticaria or worsening symptoms of CSU as AEs. However, most events occurred after cessation of treatment, suggesting that relief from CSU symptoms correlated with exposure to fenebrutinib. Nonserious, reversible and asymptomatic serum transaminase elevations occurred in the two higher fenebrutinib dose groups; none of the cases met the definition of severe drug-induced liver injury (Hy’s law)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Guidance for industry. Drug-induced Liver Injury: Premarketing Clinical Evaluation. Drug Safety (U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, 2009); 
                  https://www.fda.gov/media/116737/download
                  
                " href="/articles/s41591-021-01537-w#ref-CR38" id="ref-link-section-d72534159e3679">38</a></sup> at any dose. Similarly, a low rate of transient, nonserious transaminase elevations was observed with fenebrutinib in the rheumatoid arthritis and lupus studies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Isenberg, D. et al. Efficacy, safety, and pharmacodynamic effects of Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 
                  https://doi.org/10.1002/art.41811
                  
                 (2021)." href="/articles/s41591-021-01537-w#ref-CR34" id="ref-link-section-d72534159e3683">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Cohen, S. et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study). Arthritis Rheumatol. 72, 1435–1446 (2020)." href="/articles/s41591-021-01537-w#ref-CR35" id="ref-link-section-d72534159e3686">35</a></sup>. Elevations in transaminases have also been observed with other BTK inhibitors, indicating that these results are probably a class effect<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Montalban, X. et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N. Engl. J. Med. 380, 2406–2417 (2019)." href="/articles/s41591-021-01537-w#ref-CR50" id="ref-link-section-d72534159e3690">50</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 51" title="Atallah, E. et al. Zanubrutinib-induced liver injury: a case report and literature review. BMC Gastroenterol. 21, 244 (2021)." href="/articles/s41591-021-01537-w#ref-CR51" id="ref-link-section-d72534159e3693">51</a></sup>.</p><p>Limitations of this trial included the inability to assess fenebrutinib efficacy beyond the eight-week treatment period and lack of data on prior clinical response to omalizumab at baseline for further analysis. In addition, quality of life was not directly measured in this study to complement the UAS7 data. Because the study objectives of characterizing fenebrutinib safety and pharmacokinetics in patients with CSU were met, leading to the early stopping of the study, it is possible that observed efficacy estimates are biased upward. Efficacy in males and non-white populations is unknown because the trial mostly enrolled females from North America and Europe. Additionally, while our results suggested better efficacy in patients with type IIb autoimmunity markers, our analysis was limited because of small numbers of patients in this subset. Although we were unable to directly compare fenebrutinib efficacy with other treatments because of the lack of an active comparator arm, reductions in UAS7 at eight weeks with fenebrutinib treatment (relative to placebo) appear to be similar to omalizumab in phase 3 studies of CSU<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Kaplan, A. et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J. Allergy Clin. Immunol. 132, 101–109 (2013)." href="#ref-CR52" id="ref-link-section-d72534159e3701">52</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Maurer, M. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 368, 924–935 (2013)." href="#ref-CR53" id="ref-link-section-d72534159e3701_1">53</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54" title="Saini, S. S. et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J. Invest. Dermatol. 135, 67–75 (2015)." href="/articles/s41591-021-01537-w#ref-CR54" id="ref-link-section-d72534159e3704">54</a></sup>, and the most efficacious doses of ligelizumab, in a recently published phase 2 study<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Maurer, M. et al. Ligelizumab for chronic spontaneous urticaria. N. Engl. J. Med. 381, 1321–1332 (2019)." href="/articles/s41591-021-01537-w#ref-CR20" id="ref-link-section-d72534159e3708">20</a></sup>. In the future treatment landscape, BTK inhibitors may represent an alternative to anti-IgE therapy, with a particular role in patients with type IIb autoimmunity who are more refractory or slower to respond to anti-IgE therapy. Further studies of fenebrutinib in CSU are not currently planned; however, these data provide an insight into CSU pathophysiology to facilitate future research and development efforts in CSU by Genentech (the trial sponsor). Fenebrutinib is in phase 3 clinical trials for multiple sclerosis.</p><p>In conclusion, selective BTK inhibition by fenebrutinib diminished clinical signs and symptoms in patients with CSU refractory to up to fourfold the approved dose of H<sub>1</sub> antihistamines. Across all doses, even those associated with submaximal BTK inhibition, fenebrutinib resulted in clinical benefit for patients with CSU with type IIb autoimmunity, a population that is more refractory to currently available treatments. These findings highlight the potential for treatments that target BTK to address alternate routes of mast cell activation in diseases such as CSU.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec11-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec11">Methods</h2><div class="c-article-section__content" id="Sec11-content"><h3 class="c-article__sub-heading" id="Sec12">Study design</h3><p>This phase 2, multicenter, randomized, double-blind, placebo-controlled study was conducted at 21 centers in Canada, Germany and the US. Screening started 1 May 2017 in Canada, the first patient was enrolled on 26 May 2017, the last patient last visit was on 25 October 2019 and the database was locked on 13 December 2019. Standard site outreach and physician referrals were utilized for patient recruitment. Patients were identified from 21 dermatology, allergy and clinical centers in Germany, Canada and the US. Potentially eligible patients were invited to take part in the study.</p><p>Nonbinding interim analyses with prespecified decision criteria were preplanned for both cohorts 1 and 2; preplanned adaptations were the amendment of the study to add cohort 2 (cohort 1 interim analysis) and stopping enrollment (cohort 2). Dosing regimens (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01537-w#Fig4">1</a>) were selected using pharmacokinetic/pharmacodynamic modeling based on studies in healthy individuals<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Herman, A. E. et al. Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton’s tyrosine kinase inhibitor. Clin. Pharmacol. Ther. 103, 1020–1028 (2018)." href="/articles/s41591-021-01537-w#ref-CR33" id="ref-link-section-d72534159e3735">33</a></sup> and were associated with plasma concentrations projected to achieve BTK inhibition of approximately 70–90%. Patients were permitted to use a single approved dose of loratadine (10 mg maximum) or cetirizine (10 mg maximum) within a 24-h period as rescue medication if symptoms worsened.</p><p>The study was originally designed as a pilot study to enable initial assessment of the clinical efficacy in CSU. The 200 mg dose was selected because it was expected to be well-tolerated and substantially inhibit BTK activity, based on results from the phase 1 studies. On the basis of the pharmacokinetic and pharmacokinetic/pharmacodynamic models constructed using data from relative bioavailability, and the phase 1 studies, the 200 mg twice daily dose was expected to provide a steady-state exposure achieving 90% maximal inhibitory concentration over the entire dosing interval in &gt;75% of patients. The extent of target engagement required for clinical efficacy was unknown. Based on results from an interim analysis of the pilot study (cohort 1), a dose-ranging cohort (cohort 2) was initiated. Because the extent of target engagement required for clinical efficacy was unknown, doses for cohort 2 were selected to evaluate a range of target engagement and characterize the dose– and exposure–response relationships for safety and efficacy to select the optimal dose. As a result, replication was not performed for the 50 mg and 150 mg doses.</p><p>The study protocol was approved by central institutional review boards for the US/Canada and Germany (<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">Supplementary Information</a>). The study was conducted according to international guidelines including the Declaration of Helsinki (2013) and Council for International Organizations of Medical Sciences International Ethical Guidelines, Good Clinical Practice guidelines and applicable laws of other countries. Periodic safety reviews and interim analyses were performed by an internal monitoring committee that was unblinded to treatment assignments and did not have direct contact with patients, investigational staff or site monitors. The internal monitoring committee included representatives from clinical science, drug safety, biostatistics and statistical programming and analysis.</p><h3 class="c-article__sub-heading" id="Sec13">Patients</h3><p>Eligible patients were 18–75 years old, had CSU for ≥6 months and were symptomatic despite treatment with H<sub>1</sub> antihistamines (up to fourfold the approved dose). Key inclusion criteria were: weekly UAS7 ≥ 16, on stable doses of H<sub>1</sub> antihistamines starting at least 3 consecutive days immediately before the screening visit and continuing through day 1 (≥17 days total); completion of the urticaria patient daily eDiary in the 7 days before randomization; and no evidence of active or latent tuberculosis. Key exclusion criteria were: omalizumab treatment for CSU within four months before screening or primary nonresponse to omalizumab; other disease with wheals or angioedema; other itch-associated skin disease; routine systemic or topical corticosteroids or cyclosporine use; prior use of intravenous glucocorticoids for treatment of laryngeal angioedema; history of anaphylactic shock without clearly identifiable avoidable antigen; active infection; live or attenuated vaccine use; and any condition possibly affecting oral drug absorption. All patients provided written, informed consent. Patients were not compensated for participation in the trial.</p><h3 class="c-article__sub-heading" id="Sec14">Randomization and masking</h3><p>Genentech provided the specifications for an interactive voice/web-based response system (IxRS) with a stratified permuted blocks randomization scheme with stratification by country. The IxRS randomly allocated patients to each of four treatment arms (approximately 1:1:1:1; cohort 2) or to 200 mg oral twice daily of fenebrutinib or placebo (approximately 2:1; cohort 1). Genentech provided 50 mg fenebrutinib and matching placebo tablets.</p><p>Patients and study site personnel were blinded to individual treatment assignments throughout the study. Results of assessments that might have unblinded investigators to patient treatments, other than local standard and safety laboratory data, were not provided to site staff. During the trial, Genentech personnel, except for members of the IMC, monitored blinded clinical and safety data and had access to unblinded data if needed for safety evaluations. The internal monitoring committee was also responsible for reviewing the results of the preplanned interim analyses.</p><h3 class="c-article__sub-heading" id="Sec15">Procedures</h3><p>Patients received complete physical examinations at the day −14 visit and at the safety follow-up visit on day 85 or 4 weeks after the last dose, if the patient discontinued the study and/or study treatment. All patients took fenebrutinib and/or placebo tablets orally twice daily (every 12 h) to maintain blinding, with morning fenebrutinib doses administered in the clinic on days 1, 8 and 29, after all predose assessments. Mandatory morning visits occurred on days 1, 8, 29, 57 and 85. The last dose was taken on day 56.</p><p>Patients completed a daily electronic diary (eDiary) comprising questions regarding largest hive size, sleep interference score, activity interference, rescue medication use, angioedema episodes, number of calls to a doctor or nurse practitioner and study medication compliance. The eDiary was completed twice per day (morning and evening) during the study and was used to calculate the UAS7. The UAS is a composite score with numeric severity intensity ratings (0 = none to 3 = intense/severe) for (1) the number of wheals (hives) and (2) the intensity of the pruritus (itch) over the prior 12 h. The daily UAS equals the average of morning and evening scores. The UAS7 is the weekly sum of the daily UAS (maximum value of 42). The urticaria control test (UCT), a four-item questionnaire, assesses disease activity. The recall period is 4 weeks and the score range is 0–16 with an MID of 2.8 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 55" title="Kulthanan, K. et al. Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). Health Qual. Life Outcomes 14, 61 (2016)." href="/articles/s41591-021-01537-w#ref-CR55" id="ref-link-section-d72534159e3782">55</a></sup>). Patients completed the UCT at baseline (day 1) and on days 29, 57 and 85 for both cohorts.</p><p>For biomarker assessments, serum samples were collected at screening and on days 1, 57 and 85. For details on the BHRA and IgG-anti-FcεRI assays, see the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">Supplementary Information</a>.</p><h3 class="c-article__sub-heading" id="Sec16">End points</h3><p>The primary end point was change from baseline in the UAS7 at week 8. Secondary end points were change from baseline in UAS7 at week 4 and proportion of patients well-controlled (UAS7 ≤ 6) at week 8. Other exploratory efficacy end points included proportion of patients well-controlled at week 4, change from baseline in weekly itch score at weeks 4 and 8, change from baseline in weekly hive score at weeks 4 and 8, proportion of patients who achieved complete response (UAS7 = 0) at weeks 4 and 8, proportion of patients achieving the MID in UAS7 (reduction from baseline UAS7 ≥ 11)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56" title="Mathias, S. D., Crosby, R. D., Zazzali, J. L., Maurer, M. &amp; Saini, S. S. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann. Allergy Asthma Immunol. 108, 20–24 (2012)." href="/articles/s41591-021-01537-w#ref-CR56" id="ref-link-section-d72534159e3801">56</a></sup> at weeks 4 and 8 and time to achieving MID in UAS7. Safety end points were the incidence and severity of AEs, and changes in vital signs, physical examination findings, electrocardiograms and clinical laboratory results.</p><h3 class="c-article__sub-heading" id="Sec17">BHRA</h3><p>The BHRA was measured using sera collected at screening or week 0 for each patient by Viracor Eurofins Clinical Diagnostics, as described previously by Cho and colleagues<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Cho, C. B. et al. Autoantibodies in chronic idiopathic urticaria and nonurticarial systemic autoimmune disorders. Ann. Allergy Asthma Immunol. 110, 29–33 (2013)." href="/articles/s41591-021-01537-w#ref-CR28" id="ref-link-section-d72534159e3813">28</a></sup>. The BHRA was not measured for two patients due to sample unavailability.</p><p>Percentage histamine release was defined as: HR<sub>sample</sub>/HR<sub>total</sub> × 100, where HR<sub>sample</sub> is the histamine released by donor basophils in response to buffer, patient or healthy control serum, or anti-IgE as a positive control, and HR<sub>total</sub> is the total histamine in lysed donor basophils. The BHRA values were defined as: %HR<sub>sample</sub>/%HR<sub>healthy</sub> × 10, where %HR<sub>sample</sub> is the percentage histamine release in response to patient serum and %HR<sub>healthy</sub> is the mean percentage histamine release plus 2 s.d. in response to a panel of 5 healthy control serum samples. Samples with values ≥10 were considered BHRA<sup>+</sup>.</p><h3 class="c-article__sub-heading" id="Sec18">IgG-anti-FcεRI ELISA</h3><p>Recombinant human FcεR1a (rhFCER1A; Val26-Gln205 with a C-terminal 6-His tag; R&amp;D Systems) was used to coat ELISA plates (Nunc MaxiSorp) at 2 µg ml<sup>−1</sup> in PBS at 4 °C (for 18–72 h). On the day of the assay, plates were washed and blocked with ChonBlock Blocking/Sample Dilution Buffer (Chondrex) on a plate shaker for 2 h at room temperature. All washes in the protocol were as follows: three times with wash buffer (PBS, 0.05% Tween 20). Serum samples from patients with CSU were diluted 1:50 in ChonBlock Blocking/Sample Dilution Buffer, spiked with rhFCER1A or a nonspecific control protein (recombinant human PD-1; Leu25-Thr168 with a C-terminal 6-His tag; R&amp;D Systems) at a final concentration of 2.5 µg ml<sup>−1</sup> and incubated on a plate shaker for 1 h at room temperature. A mouse IgG × FCER1A (Abcam) standard curve (6-point, threefold dilution series, 0.014–10 ng ml<sup>−1</sup>) was prepared in ChonBlock Blocking/Sample Dilution Buffer. Plates were washed, samples and standards were added to the wells (in duplicate) and plates were incubated on a plate shaker for 2 h at room temperature. Goat × mouse IgG (minimal cross-reactivity), horseradish peroxidase (BioLegend) and AffiniPure Goat Anti-Human IgG-Fcγ (minimum cross-reactivity) (Jackson ImmunoResearch) were diluted in ChonBlock Detection Antibody Dilution Buffer (Chondrex) (1:8,000 and 1:10,000, respectively). Plates were washed, secondary antibodies were added to the appropriate wells and plates were incubated on a plate shaker for 1 h at room temperature. Plates were washed, 3,3′,5,5′-tetramethylbenzidine substrate solution (SeraCare) was added to all wells and plates were incubated on a plate shaker for 5–10 min at room temperature. The substrate reaction was stopped by adding 1 M of phosphoric acid and absorbance (450 and 630 nm) was read on a spectrophotometric plate reader (Molecular Devices VersaMax).</p><p>For each well, the 630 nm reading was subtracted from the 450 nm reading. Nonlinear regression curve fitting of the mouse IgG × FCER1A standard was performed and the calculated concentration of each serum sample (ng ml<sup>−1</sup>) was determined using Prism v.6 (GraphPad Software). Relative IgG-anti-FcεRI reactivity was determined by subtracting the sample concentrations from serum preincubated with rhFCER1A from the same serum sample preincubated with rhPD-1. For each experiment, the relative IgG-anti-FcεRI reactivity was determined for a set of 16 healthy volunteer samples and the mean + 3 s.d. was defined as the upper normal range (UNR) threshold, which varied slightly between experiments. Values ≤UNR were considered IgG-anti-FcεRI<sup>−</sup> and values &gt;UNR were considered IgG-anti-FcεRI<sup>+</sup>. To calculate the percentage change from baseline (in patients who were IgG-anti-FcεRI<sup>+</sup> at baseline), values &lt;UNR were set to the UNR and the following formula was used: RR(week 8) − RR(Baseline)/RR(Baseline) × 100, where RR is the relative IgG-anti-FcεRI reactivity for a given patient sample.</p><h3 class="c-article__sub-heading" id="Sec19">Statistical analysis</h3><p>The purpose of this phase 2 study was initial efficacy estimation and hypothesis generation. Assuming an s.d. of 13, a two-sided alpha level of 0.10 and a 10% dropout rate at week 8, we estimated that a sample size of 30 patients per arm provided approximately 90% power to detect an 11-point difference in the UAS7 change from baseline at week 8 between treatment groups. No adjustment of sample size based on the results of nonbinding interim analysis took place.</p><p>Efficacy analyses were conducted for all patients who received at least one dose of study treatment with patients grouped according to treatment assigned at randomization (that is, the modified intent-to-treat population); safety analyses were conducted for the safety population, with patients grouped according to actual treatment received. No participants were excluded from analysis. An internal monitoring committee periodically reviewed safety and performed interim analyses. Preplanned interim efficacy and safety analyses were specified in the protocol (<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">Supplementary Information</a>). Biomarker analyses were prespecified in a separate biomarker analysis plan (<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">Supplementary Information</a>) before the interim analysis readout.</p><p>A nonbinding interim analysis was planned and conducted for the time point once 80 patients in cohort 2 had efficacy assessments at week 4. Due to the hypothesis-generating nature of the study, no adjustment was made for sample size at the planning stage of the study to account for the interim look; no adjustment for confidence intervals (CIs) or <i>P</i> values obtained in the analysis was implemented. The decision criteria for the efficacy parameters were established using a normal Bayesian model to assess the posterior probability of seeing an equal or higher than prespecified effect size in a future phase 3 CSU trial assuming mean parameter density distribution calculated from the non-informative prior and the phase 2b interim analysis data and known s.d. Cutoffs were based on the chances of meeting an efficacy threshold in phase 3 of &gt;60% (go) or &lt;25% (no go).</p><p>Differences between fenebrutinib and placebo groups for continuous efficacy end points, including the primary end point, were analyzed using a mixed model for repeated measures (MMRM) with an unstructured covariance pattern for within-participant errors. Restricted maximum likelihood with the Kenward–Roger approximation for the denominator d.f. was used for the parameter estimates. The MMRM method assumes that data are missing at random<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 57" title="O’Kelly, M. &amp; Ratitch, B. Clinical Trials with Missing Data: a Guide for Practitioners (John Wiley &amp; Sons, 2014)." href="/articles/s41591-021-01537-w#ref-CR57" id="ref-link-section-d72534159e3890">57</a></sup>. High correlation between successive observations on an individual allows data from individuals who dropped out to contribute to the estimation of the effects at the final time point. All MMRM models included country, treatment group, visit and visit by treatment group interaction as covariates. As sensitivity analyses, analysis of covariance models were fitted with missing week 8 data imputed by last observation carried forward and best observation carried forward. Categorical end points were summarized as proportions; patients who discontinued treatment before the reporting time point were considered nonresponders. Kaplan–Meier estimates were used to analyze time-to-event end points.</p><p>The changes from baseline in UAS7 versus placebo are reported for the BHRA subsets as least squares mean differences based on the same model used for the primary analysis but including the BHRA subset indicator and visit-by-arm-by-BHRA interaction. A Spearman correlation was used to assess the relationship between percentage change from baseline in IgG-anti-FcεRI versus change from baseline in UAS7.</p><p>No multiple comparison adjustments were made and point estimates with unadjusted 95% CIs are reported. Statistical analyses were performed using SAS v.9.4 (SAS Institute) and R v.3.6.1 (<a href="https://www.r-project.org/">https://www.r-project.org/</a>).</p><h3 class="c-article__sub-heading" id="Sec20">Reporting Summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM2">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>The study protocol and biomarker analysis plan are provided in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01537-w#MOESM1">Supplementary Material</a>. As per the Roche Global Policy on Sharing of Clinical Study Information, Roche supports data sharing with qualified investigators engaged in rigorous, independent scientific research. The data for this study were available as of October 2020. Access to Roche’s de-identified patient-level data is facilitated through the cross-industry request Vivli site at <a href="https://vivli.org/">https://vivli.org</a>. Requests for access to Roche data are made through the Vivli process and supported by a research proposal that is assessed by an independent review panel managed by the Wellcome Trust. The panel considers the scientific merit of each application. This independent group then decides whether or not the data should be provided. On average it takes a few months to access data in the Vivli platform but the timeline will vary depending on the number of data contributors, the number of studies and your availability to respond to comments. Analyses performed on the data must be in line with the purpose outlined in the research proposal and be approved by the independent review panel. The mechanisms for how data will be made available on the platform are outlined on the Vivli website (<a href="https://vivli.org/about/data-request-review-process/">https://vivli.org/about/data-request-review-process/</a>). The Vivli secure research environment allows research teams to access data and conduct analyses in a shared workspace that is equipped with analytical tools and may be flexibly configured. The download of Roche anonymized patient-level data from the secure environment is not permitted. For further restrictions and information, please visit <a href="https://vivli.org">https://vivli.org</a>. Further details on Roche’s criteria for eligible studies are available at <a href="https://vivli.org/members/ourmembers/">https://vivli.org/members/ourmembers/</a>. Further details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents can be accessed at <a href="https://go.gene.com/datasharing">https://go.gene.com/datasharing</a>.</p>
            </div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Zuberbier, T. et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy</i> <b>73</b>, 1393–1414 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/all.13397" data-track-item_id="10.1111/all.13397" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fall.13397" aria-label="Article reference 1" data-doi="10.1111/all.13397">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC1MvgvFeqsA%3D%3D" aria-label="CAS reference 1">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29336054" aria-label="PubMed reference 1">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20EAACI%2FGA%C2%B2LEN%2FEDF%2FWAO%20guideline%20for%20the%20definition%2C%20classification%2C%20diagnosis%20and%20management%20of%20urticaria&amp;journal=Allergy&amp;doi=10.1111%2Fall.13397&amp;volume=73&amp;pages=1393-1414&amp;publication_year=2018&amp;author=Zuberbier%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Fricke, J. et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. <i>Allergy</i> <b>75</b>, 423–432 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/all.14037" data-track-item_id="10.1111/all.14037" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fall.14037" aria-label="Article reference 2" data-doi="10.1111/all.14037">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31494963" aria-label="PubMed reference 2">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Prevalence%20of%20chronic%20urticaria%20in%20children%20and%20adults%20across%20the%20globe%3A%20systematic%20review%20with%20meta-analysis&amp;journal=Allergy&amp;doi=10.1111%2Fall.14037&amp;volume=75&amp;pages=423-432&amp;publication_year=2020&amp;author=Fricke%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Kolkhir, P. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. <i>J. Allergy Clin. Immunol.</i> <b>139</b>, 1772–1781.e1 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2016.08.050" data-track-item_id="10.1016/j.jaci.2016.08.050" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2016.08.050" aria-label="Article reference 3" data-doi="10.1016/j.jaci.2016.08.050">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhvFKnsbfJ" aria-label="CAS reference 3">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27777182" aria-label="PubMed reference 3">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Autoimmune%20chronic%20spontaneous%20urticaria%3A%20what%20we%20know%20and%20what%20we%20do%20not%20know&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2016.08.050&amp;volume=139&amp;pages=1772-1781.e1&amp;publication_year=2017&amp;author=Kolkhir%2CP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Schmetzer, O. et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. <i>J. Allergy Clin. Immunol.</i> <b>142</b>, 876–882 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2017.10.035" data-track-item_id="10.1016/j.jaci.2017.10.035" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2017.10.035" aria-label="Article reference 4" data-doi="10.1016/j.jaci.2017.10.035">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXjvFGqtQ%3D%3D" aria-label="CAS reference 4">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29208545" aria-label="PubMed reference 4">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=IL-24%20is%20a%20common%20and%20specific%20autoantigen%20of%20IgE%20in%20patients%20with%20chronic%20spontaneous%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2017.10.035&amp;volume=142&amp;pages=876-882&amp;publication_year=2018&amp;author=Schmetzer%2CO">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Niu, X. L. et al. Association of positive and negative autologous serum skin test responses with clinical features of chronic spontaneous urticaria in Asian patients: a systematic review and meta-analysis. <i>Exp. Ther. Med.</i> <b>17</b>, 2603–2613 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30906452" aria-label="PubMed reference 5">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425266" aria-label="PubMed Central reference 5">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20of%20positive%20and%20negative%20autologous%20serum%20skin%20test%20responses%20with%20clinical%20features%20of%20chronic%20spontaneous%20urticaria%20in%20Asian%20patients%3A%20a%20systematic%20review%20and%20meta-analysis&amp;journal=Exp.%20Ther.%20Med.&amp;volume=17&amp;pages=2603-2613&amp;publication_year=2019&amp;author=Niu%2CXL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Altrichter, S. et al. Total IgE as a marker for chronic spontaneous urticaria. <i>Allergy Asthma Immunol. Res.</i> <b>13</b>, 206–218 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4168/aair.2021.13.2.206" data-track-item_id="10.4168/aair.2021.13.2.206" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4168%2Faair.2021.13.2.206" aria-label="Article reference 6" data-doi="10.4168/aair.2021.13.2.206">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsFWiu7%2FN" aria-label="CAS reference 6">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33474856" aria-label="PubMed reference 6">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840871" aria-label="PubMed Central reference 6">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Total%20IgE%20as%20a%20marker%20for%20chronic%20spontaneous%20urticaria&amp;journal=Allergy%20Asthma%20Immunol.%20Res.&amp;doi=10.4168%2Faair.2021.13.2.206&amp;volume=13&amp;pages=206-218&amp;publication_year=2021&amp;author=Altrichter%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Altrichter, S. et al. IgE mediated autoallergy against thyroid peroxidase––a novel pathomechanism of chronic spontaneous urticaria? <i>PLoS ONE</i> <b>6</b>, e14794 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0014794" data-track-item_id="10.1371/journal.pone.0014794" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0014794" aria-label="Article reference 7" data-doi="10.1371/journal.pone.0014794">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXltV2mtb0%3D" aria-label="CAS reference 7">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21532759" aria-label="PubMed reference 7">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075251" aria-label="PubMed Central reference 7">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=IgE%20mediated%20autoallergy%20against%20thyroid%20peroxidase%E2%80%93%E2%80%93a%20novel%20pathomechanism%20of%20chronic%20spontaneous%20urticaria%3F&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0014794&amp;volume=6&amp;publication_year=2011&amp;author=Altrichter%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Maurer, M. et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. <i>J. Allergy Clin. Immunol.</i> <b>128</b>, 202–209.e5 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2011.04.038" data-track-item_id="10.1016/j.jaci.2011.04.038" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2011.04.038" aria-label="Article reference 8" data-doi="10.1016/j.jaci.2011.04.038">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXosFakurk%3D" aria-label="CAS reference 8">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21636116" aria-label="PubMed reference 8">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20and%20safety%20of%20omalizumab%20in%20patients%20with%20chronic%20urticaria%20who%20exhibit%20IgE%20against%20thyroperoxidase&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2011.04.038&amp;volume=128&amp;pages=202-209.e5&amp;publication_year=2011&amp;author=Maurer%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Lakin, E., Church, M. K., Maurer, M. &amp; Schmetzer, O. On the lipophilic nature of autoreactive IgE in chronic spontaneous urticaria. <i>Theranostics</i> <b>9</b>, 829–836 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.7150/thno.29902" data-track-item_id="10.7150/thno.29902" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.7150%2Fthno.29902" aria-label="Article reference 9" data-doi="10.7150/thno.29902">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtlGqsrrN" aria-label="CAS reference 9">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30809311" aria-label="PubMed reference 9">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376472" aria-label="PubMed Central reference 9">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=On%20the%20lipophilic%20nature%20of%20autoreactive%20IgE%20in%20chronic%20spontaneous%20urticaria&amp;journal=Theranostics&amp;doi=10.7150%2Fthno.29902&amp;volume=9&amp;pages=829-836&amp;publication_year=2019&amp;author=Lakin%2CE&amp;author=Church%2CMK&amp;author=Maurer%2CM&amp;author=Schmetzer%2CO">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Asero, R. et al. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. <i>Clin. Exp. Immunol.</i> <b>200</b>, 242–249 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/cei.13428" data-track-item_id="10.1111/cei.13428" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fcei.13428" aria-label="Article reference 10" data-doi="10.1111/cei.13428">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXpsFOhurg%3D" aria-label="CAS reference 10">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32115683" aria-label="PubMed reference 10">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231996" aria-label="PubMed Central reference 10">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Co-occurrence%20of%20IgE%20and%20IgG%20autoantibodies%20in%20patients%20with%20chronic%20spontaneous%20urticaria&amp;journal=Clin.%20Exp.%20Immunol.&amp;doi=10.1111%2Fcei.13428&amp;volume=200&amp;pages=242-249&amp;publication_year=2020&amp;author=Asero%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Hide, M. et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. <i>N. Engl. J. Med.</i> <b>328</b>, 1599–1604 (1993).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJM199306033282204" data-track-item_id="10.1056/NEJM199306033282204" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJM199306033282204" aria-label="Article reference 11" data-doi="10.1056/NEJM199306033282204">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DyaK3s3lsVGjsw%3D%3D" aria-label="CAS reference 11">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=7683772" aria-label="PubMed reference 11">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Autoantibodies%20against%20the%20high-affinity%20IgE%20receptor%20as%20a%20cause%20of%20histamine%20release%20in%20chronic%20urticaria&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJM199306033282204&amp;volume=328&amp;pages=1599-1604&amp;publication_year=1993&amp;author=Hide%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Sánchez, J., Sánchez, A. &amp; Cardona, R. Causal relationship between anti-TPO IgE and chronic urticaria by in vitro and in vivo tests. <i>Allergy Asthma Immunol. Res.</i> <b>11</b>, 29–42 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4168/aair.2019.11.1.29" data-track-item_id="10.4168/aair.2019.11.1.29" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4168%2Faair.2019.11.1.29" aria-label="Article reference 12" data-doi="10.4168/aair.2019.11.1.29">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30479075" aria-label="PubMed reference 12">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Causal%20relationship%20between%20anti-TPO%20IgE%20and%20chronic%20urticaria%20by%20in%20vitro%20and%20in%20vivo%20tests&amp;journal=Allergy%20Asthma%20Immunol.%20Res.&amp;doi=10.4168%2Faair.2019.11.1.29&amp;volume=11&amp;pages=29-42&amp;publication_year=2019&amp;author=S%C3%A1nchez%2CJ&amp;author=S%C3%A1nchez%2CA&amp;author=Cardona%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Gruber, B. L., Baeza, M. L., Marchese, M. J., Agnello, V. &amp; Kaplan, A. P. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. <i>J. Invest. Dermatol.</i> <b>90</b>, 213–217 (1988).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/1523-1747.ep12462239" data-track-item_id="10.1111/1523-1747.ep12462239" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2F1523-1747.ep12462239" aria-label="Article reference 13" data-doi="10.1111/1523-1747.ep12462239">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DyaL1c7hs1yisw%3D%3D" aria-label="CAS reference 13">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2448392" aria-label="PubMed reference 13">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Prevalence%20and%20functional%20role%20of%20anti-IgE%20autoantibodies%20in%20urticarial%20syndromes&amp;journal=J.%20Invest.%20Dermatol.&amp;doi=10.1111%2F1523-1747.ep12462239&amp;volume=90&amp;pages=213-217&amp;publication_year=1988&amp;author=Gruber%2CBL&amp;author=Baeza%2CML&amp;author=Marchese%2CMJ&amp;author=Agnello%2CV&amp;author=Kaplan%2CAP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Grattan, C. E., Francis, D. M., Hide, M. &amp; Greaves, M. W. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. <i>Clin. Exp. Allergy</i> <b>21</b>, 695–704 (1991).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/j.1365-2222.1991.tb03198.x" data-track-item_id="10.1111/j.1365-2222.1991.tb03198.x" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fj.1365-2222.1991.tb03198.x" aria-label="Article reference 14" data-doi="10.1111/j.1365-2222.1991.tb03198.x">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DyaK387js1WlsA%3D%3D" aria-label="CAS reference 14">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=1723343" aria-label="PubMed reference 14">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Detection%20of%20circulating%20histamine%20releasing%20autoantibodies%20with%20functional%20properties%20of%20anti-IgE%20in%20chronic%20urticaria&amp;journal=Clin.%20Exp.%20Allergy&amp;doi=10.1111%2Fj.1365-2222.1991.tb03198.x&amp;volume=21&amp;pages=695-704&amp;publication_year=1991&amp;author=Grattan%2CCE&amp;author=Francis%2CDM&amp;author=Hide%2CM&amp;author=Greaves%2CMW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Niimi, N. et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. <i>J. Invest. Dermatol.</i> <b>106</b>, 1001–1006 (1996).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/1523-1747.ep12338544" data-track-item_id="10.1111/1523-1747.ep12338544" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2F1523-1747.ep12338544" aria-label="Article reference 15" data-doi="10.1111/1523-1747.ep12338544">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK28Xjs1Shtb8%3D" aria-label="CAS reference 15">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8618029" aria-label="PubMed reference 15">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Dermal%20mast%20cell%20activation%20by%20autoantibodies%20against%20the%20high%20affinity%20IgE%20receptor%20in%20chronic%20urticaria&amp;journal=J.%20Invest.%20Dermatol.&amp;doi=10.1111%2F1523-1747.ep12338544&amp;volume=106&amp;pages=1001-1006&amp;publication_year=1996&amp;author=Niimi%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Kikuchi, Y. &amp; Kaplan, A. P. Mechanism of autoimmune activation of basophils in chronic urticaria. <i>J. Allergy Clin. Immunol.</i> <b>107</b>, 1056–1062 (2001).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1067/mai.2001.115484" data-track-item_id="10.1067/mai.2001.115484" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1067%2Fmai.2001.115484" aria-label="Article reference 16" data-doi="10.1067/mai.2001.115484">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD3MXkvFelsLw%3D" aria-label="CAS reference 16">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11398085" aria-label="PubMed reference 16">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Mechanism%20of%20autoimmune%20activation%20of%20basophils%20in%20chronic%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1067%2Fmai.2001.115484&amp;volume=107&amp;pages=1056-1062&amp;publication_year=2001&amp;author=Kikuchi%2CY&amp;author=Kaplan%2CAP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Kikuchi, Y. &amp; Kaplan, A. P. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. <i>J. Allergy Clin. Immunol.</i> <b>109</b>, 114–118 (2002).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1067/mai.2002.120954" data-track-item_id="10.1067/mai.2002.120954" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1067%2Fmai.2002.120954" aria-label="Article reference 17" data-doi="10.1067/mai.2002.120954">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD38XhsVWltr4%3D" aria-label="CAS reference 17">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11799375" aria-label="PubMed reference 17">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20role%20for%20C5a%20in%20augmenting%20IgG-dependent%20histamine%20release%20from%20basophils%20in%20chronic%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1067%2Fmai.2002.120954&amp;volume=109&amp;pages=114-118&amp;publication_year=2002&amp;author=Kikuchi%2CY&amp;author=Kaplan%2CAP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Kaplan, A. P. Chronic spontaneous urticaria: pathogenesis and treatment considerations. <i>Allergy Asthma Immunol. Res.</i> <b>9</b>, 477–482 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4168/aair.2017.9.6.477" data-track-item_id="10.4168/aair.2017.9.6.477" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4168%2Faair.2017.9.6.477" aria-label="Article reference 18" data-doi="10.4168/aair.2017.9.6.477">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXksVCitLk%3D" aria-label="CAS reference 18">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28913986" aria-label="PubMed reference 18">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603475" aria-label="PubMed Central reference 18">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Chronic%20spontaneous%20urticaria%3A%20pathogenesis%20and%20treatment%20considerations&amp;journal=Allergy%20Asthma%20Immunol.%20Res.&amp;doi=10.4168%2Faair.2017.9.6.477&amp;volume=9&amp;pages=477-482&amp;publication_year=2017&amp;author=Kaplan%2CAP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Kaplan, A. et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. <i>J. Allergy Clin. Immunol.</i> <b>137</b>, 474–481 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2015.08.023" data-track-item_id="10.1016/j.jaci.2015.08.023" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2015.08.023" aria-label="Article reference 19" data-doi="10.1016/j.jaci.2015.08.023">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhs1yjsLzJ" aria-label="CAS reference 19">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26483177" aria-label="PubMed reference 19">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Timing%20and%20duration%20of%20omalizumab%20response%20in%20patients%20with%20chronic%20idiopathic%2Fspontaneous%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2015.08.023&amp;volume=137&amp;pages=474-481&amp;publication_year=2016&amp;author=Kaplan%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Maurer, M. et al. Ligelizumab for chronic spontaneous urticaria. <i>N. Engl. J. Med.</i> <b>381</b>, 1321–1332 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1900408" data-track-item_id="10.1056/NEJMoa1900408" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1900408" aria-label="Article reference 20" data-doi="10.1056/NEJMoa1900408">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXnsFCmu7c%3D" aria-label="CAS reference 20">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31577874" aria-label="PubMed reference 20">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Ligelizumab%20for%20chronic%20spontaneous%20urticaria&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1900408&amp;volume=381&amp;pages=1321-1332&amp;publication_year=2019&amp;author=Maurer%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Zweiman, B., Valenzano, M., Atkins, P. C., Tanus, T. &amp; Getsy, J. A. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. <i>J. Allergy Clin. Immunol.</i> <b>98</b>, 89–98 (1996).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0091-6749(96)70230-0" data-track-item_id="10.1016/S0091-6749(96)70230-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0091-6749%2896%2970230-0" aria-label="Article reference 21" data-doi="10.1016/S0091-6749(96)70230-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK28Xlt1ehs7k%3D" aria-label="CAS reference 21">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8765822" aria-label="PubMed reference 21">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Characteristics%20of%20histamine-releasing%20activity%20in%20the%20sera%20of%20patients%20with%20chronic%20idiopathic%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2FS0091-6749%2896%2970230-0&amp;volume=98&amp;pages=89-98&amp;publication_year=1996&amp;author=Zweiman%2CB&amp;author=Valenzano%2CM&amp;author=Atkins%2CPC&amp;author=Tanus%2CT&amp;author=Getsy%2CJA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Sabroe, R. A. et al. Classification of anti-FcϵRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. <i>J. Allergy Clin. Immunol.</i> <b>110</b>, 492–499 (2002).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1067/mai.2002.126782" data-track-item_id="10.1067/mai.2002.126782" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1067%2Fmai.2002.126782" aria-label="Article reference 22" data-doi="10.1067/mai.2002.126782">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD38XnvVSru7c%3D" aria-label="CAS reference 22">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12209101" aria-label="PubMed reference 22">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Classification%20of%20anti-Fc%CF%B5RI%20and%20anti-IgE%20autoantibodies%20in%20chronic%20idiopathic%20urticaria%20and%20correlation%20with%20disease%20severity&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1067%2Fmai.2002.126782&amp;volume=110&amp;pages=492-499&amp;publication_year=2002&amp;author=Sabroe%2CRA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Biagtan, M. J., Viswanathan, R. K., Evans, M. D. &amp; Mathur, S. K. Clinical utility of the chronic urticaria index. <i>J. Allergy Clin. Immunol.</i> <b>127</b>, 1626–1627 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2011.01.045" data-track-item_id="10.1016/j.jaci.2011.01.045" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2011.01.045" aria-label="Article reference 23" data-doi="10.1016/j.jaci.2011.01.045">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21376378" aria-label="PubMed reference 23">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105218" aria-label="PubMed Central reference 23">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20utility%20of%20the%20chronic%20urticaria%20index&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2011.01.045&amp;volume=127&amp;pages=1626-1627&amp;publication_year=2011&amp;author=Biagtan%2CMJ&amp;author=Viswanathan%2CRK&amp;author=Evans%2CMD&amp;author=Mathur%2CSK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Gericke, J. et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. <i>J. Allergy Clin. Immunol.</i> <b>139</b>, 1059–1061.e1 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2016.07.047" data-track-item_id="10.1016/j.jaci.2016.07.047" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2016.07.047" aria-label="Article reference 24" data-doi="10.1016/j.jaci.2016.07.047">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XitVyjur3L" aria-label="CAS reference 24">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27838346" aria-label="PubMed reference 24">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Serum%20autoreactivity%20predicts%20time%20to%20response%20to%20omalizumab%20therapy%20in%20chronic%20spontaneous%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2016.07.047&amp;volume=139&amp;pages=1059-1061.e1&amp;publication_year=2017&amp;author=Gericke%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Ghazanfar, M. N., Sand, C. &amp; Thomsen, S. F. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. <i>Br. J. Dermatol.</i> <b>175</b>, 404–406 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/bjd.14540" data-track-item_id="10.1111/bjd.14540" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fbjd.14540" aria-label="Article reference 25" data-doi="10.1111/bjd.14540">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhtlGmsrjE" aria-label="CAS reference 25">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26972689" aria-label="PubMed reference 25">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Effectiveness%20and%20safety%20of%20omalizumab%20in%20chronic%20spontaneous%20or%20inducible%20urticaria%3A%20evaluation%20of%20154%20patients&amp;journal=Br.%20J.%20Dermatol.&amp;doi=10.1111%2Fbjd.14540&amp;volume=175&amp;pages=404-406&amp;publication_year=2016&amp;author=Ghazanfar%2CMN&amp;author=Sand%2CC&amp;author=Thomsen%2CSF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Kolkhir, P. et al. Reply. <i>J. Allergy Clin. Immunol.</i> <b>141</b>, 1166–1167 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2017.09.010" data-track-item_id="10.1016/j.jaci.2017.09.010" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2017.09.010" aria-label="Article reference 26" data-doi="10.1016/j.jaci.2017.09.010">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29102069" aria-label="PubMed reference 26">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Reply&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2017.09.010&amp;volume=141&amp;pages=1166-1167&amp;publication_year=2018&amp;author=Kolkhir%2CP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">De Swerdt, A. et al. Detection of basophil-activating IgG autoantibodies in chronic idiopathic urticaria by induction of CD 63. <i>J. Allergy Clin. Immunol.</i> <b>116</b>, 662–667 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2005.04.042" data-track-item_id="10.1016/j.jaci.2005.04.042" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2005.04.042" aria-label="Article reference 27" data-doi="10.1016/j.jaci.2005.04.042">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtVWhtLfP" aria-label="CAS reference 27">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16159640" aria-label="PubMed reference 27">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Detection%20of%20basophil-activating%20IgG%20autoantibodies%20in%20chronic%20idiopathic%20urticaria%20by%20induction%20of%20CD%2063&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2005.04.042&amp;volume=116&amp;pages=662-667&amp;publication_year=2005&amp;author=De%20Swerdt%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Cho, C. B. et al. Autoantibodies in chronic idiopathic urticaria and nonurticarial systemic autoimmune disorders. <i>Ann. Allergy Asthma Immunol.</i> <b>110</b>, 29–33 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.anai.2012.10.020" data-track-item_id="10.1016/j.anai.2012.10.020" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.anai.2012.10.020" aria-label="Article reference 28" data-doi="10.1016/j.anai.2012.10.020">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XhvVaqu7rJ" aria-label="CAS reference 28">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23244655" aria-label="PubMed reference 28">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901433" aria-label="PubMed Central reference 28">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Autoantibodies%20in%20chronic%20idiopathic%20urticaria%20and%20nonurticarial%20systemic%20autoimmune%20disorders&amp;journal=Ann.%20Allergy%20Asthma%20Immunol.&amp;doi=10.1016%2Fj.anai.2012.10.020&amp;volume=110&amp;pages=29-33&amp;publication_year=2013&amp;author=Cho%2CCB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Hata, D. et al. Involvement of Bruton’s tyrosine kinase in FcεRI-dependent mast cell degranulation and cytokine production. <i>J. Exp. Med.</i> <b>187</b>, 1235–1247 (1998).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1084/jem.187.8.1235" data-track-item_id="10.1084/jem.187.8.1235" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1084%2Fjem.187.8.1235" aria-label="Article reference 29" data-doi="10.1084/jem.187.8.1235">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK1cXis1Cru7k%3D" aria-label="CAS reference 29">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9547335" aria-label="PubMed reference 29">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212237" aria-label="PubMed Central reference 29">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Involvement%20of%20Bruton%E2%80%99s%20tyrosine%20kinase%20in%20Fc%CE%B5RI-dependent%20mast%20cell%20degranulation%20and%20cytokine%20production&amp;journal=J.%20Exp.%20Med.&amp;doi=10.1084%2Fjem.187.8.1235&amp;volume=187&amp;pages=1235-1247&amp;publication_year=1998&amp;author=Hata%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Kneidinger, M. et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. <i>Blood</i> <b>111</b>, 3097–3107 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2007-08-104372" data-track-item_id="10.1182/blood-2007-08-104372" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2007-08-104372" aria-label="Article reference 30" data-doi="10.1182/blood-2007-08-104372">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXjvVamtLY%3D" aria-label="CAS reference 30">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18180381" aria-label="PubMed reference 30">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20effects%20of%20dasatinib%20on%20IgE%20receptor-dependent%20activation%20and%20histamine%20release%20in%20human%20basophils&amp;journal=Blood&amp;doi=10.1182%2Fblood-2007-08-104372&amp;volume=111&amp;pages=3097-3107&amp;publication_year=2008&amp;author=Kneidinger%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Regan, J. A. et al. Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. <i>J. Allergy Clin. Immunol.</i> <b>140</b>, 875–879.e1 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2017.03.013" data-track-item_id="10.1016/j.jaci.2017.03.013" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2017.03.013" aria-label="Article reference 31" data-doi="10.1016/j.jaci.2017.03.013">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXms12rtL0%3D" aria-label="CAS reference 31">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28389390" aria-label="PubMed reference 31">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366359" aria-label="PubMed Central reference 31">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Ibrutinib%2C%20a%20Bruton%E2%80%99s%20tyrosine%20kinase%20inhibitor%20used%20for%20treatment%20of%20lymphoproliferative%20disorders%2C%20eliminates%20both%20aeroallergen%20skin%20test%20and%20basophil%20activation%20test%20reactivity&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2017.03.013&amp;volume=140&amp;pages=875-879.e1&amp;publication_year=2017&amp;author=Regan%2CJA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Dispenza, M. C. et al. Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy. <i>J. Allergy Clin. Immunol.</i> <b>141</b>, 1914–1916.e7 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2017.12.987" data-track-item_id="10.1016/j.jaci.2017.12.987" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2017.12.987" aria-label="Article reference 32" data-doi="10.1016/j.jaci.2017.12.987">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29360526" aria-label="PubMed reference 32">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297295" aria-label="PubMed Central reference 32">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Short-term%20ibrutinib%20therapy%20suppresses%20skin%20test%20responses%20and%20eliminates%20IgE-mediated%20basophil%20activation%20in%20adults%20with%20peanut%20or%20tree%20nut%20allergy&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2017.12.987&amp;volume=141&amp;pages=1914-1916.e7&amp;publication_year=2018&amp;author=Dispenza%2CMC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Herman, A. E. et al. Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton’s tyrosine kinase inhibitor. <i>Clin. Pharmacol. Ther.</i> <b>103</b>, 1020–1028 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/cpt.1056" data-track-item_id="10.1002/cpt.1056" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fcpt.1056" aria-label="Article reference 33" data-doi="10.1002/cpt.1056">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtVOqsrrK" aria-label="CAS reference 33">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29484638" aria-label="PubMed reference 33">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20pharmacokinetics%2C%20and%20pharmacodynamics%20in%20healthy%20volunteers%20treated%20with%20GDC-0853%2C%20a%20selective%20reversible%20Bruton%E2%80%99s%20tyrosine%20kinase%20inhibitor&amp;journal=Clin.%20Pharmacol.%20Ther.&amp;doi=10.1002%2Fcpt.1056&amp;volume=103&amp;pages=1020-1028&amp;publication_year=2018&amp;author=Herman%2CAE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Isenberg, D. et al. Efficacy, safety, and pharmacodynamic effects of Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. <i>Arthritis Rheumatol</i>. <a href="https://doi.org/10.1002/art.41811" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1002/art.41811">https://doi.org/10.1002/art.41811</a> (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Cohen, S. et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study). <i>Arthritis Rheumatol.</i> <b>72</b>, 1435–1446 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/art.41275" data-track-item_id="10.1002/art.41275" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fart.41275" aria-label="Article reference 35" data-doi="10.1002/art.41275">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslGitLjM" aria-label="CAS reference 35">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496340" aria-label="PubMed Central reference 35">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Fenebrutinib%20versus%20placebo%20or%20adalimumab%20in%20rheumatoid%20arthritis%3A%20a%20randomized%2C%20double-blind%2C%20phase%20II%20trial%20%28ANDES%20study%29&amp;journal=Arthritis%20Rheumatol.&amp;doi=10.1002%2Fart.41275&amp;volume=72&amp;pages=1435-1446&amp;publication_year=2020&amp;author=Cohen%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Ertas, R., Ozyurt, K., Atasoy, M., Hawro, T. &amp; Maurer, M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. <i>Allergy</i> <b>73</b>, 705–712 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/all.13345" data-track-item_id="10.1111/all.13345" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fall.13345" aria-label="Article reference 36" data-doi="10.1111/all.13345">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXjtlOqsbw%3D" aria-label="CAS reference 36">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29083482" aria-label="PubMed reference 36">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20clinical%20response%20to%20omalizumab%20in%20chronic%20spontaneous%20urticaria%20patients%20is%20linked%20to%20and%20predicted%20by%20IgE%20levels%20and%20their%20change&amp;journal=Allergy&amp;doi=10.1111%2Fall.13345&amp;volume=73&amp;pages=705-712&amp;publication_year=2018&amp;author=Ertas%2CR&amp;author=Ozyurt%2CK&amp;author=Atasoy%2CM&amp;author=Hawro%2CT&amp;author=Maurer%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Soundararajan, S., Kikuchi, Y., Joseph, K. &amp; Kaplan, A. P. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. <i>J. Allergy Clin. Immunol.</i> <b>115</b>, 815–821 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2004.12.1120" data-track-item_id="10.1016/j.jaci.2004.12.1120" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2004.12.1120" aria-label="Article reference 37" data-doi="10.1016/j.jaci.2004.12.1120">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXivV2is74%3D" aria-label="CAS reference 37">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15806004" aria-label="PubMed reference 37">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Functional%20assessment%20of%20pathogenic%20IgG%20subclasses%20in%20chronic%20autoimmune%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2004.12.1120&amp;volume=115&amp;pages=815-821&amp;publication_year=2005&amp;author=Soundararajan%2CS&amp;author=Kikuchi%2CY&amp;author=Joseph%2CK&amp;author=Kaplan%2CAP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38"><i>Guidance for industry. Drug-induced Liver Injury: Premarketing Clinical Evaluation.</i> Drug Safety (U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, 2009); <a href="https://www.fda.gov/media/116737/download" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="https://www.fda.gov/media/116737/download">https://www.fda.gov/media/116737/download</a></p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Dispenza, M. C. et al. Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. <i>J. Clin. Invest.</i> <b>130</b>, 4759–4770 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1172/JCI138448" data-track-item_id="10.1172/JCI138448" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI138448" aria-label="Article reference 39" data-doi="10.1172/JCI138448">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvVejtrjJ" aria-label="CAS reference 39">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32484802" aria-label="PubMed reference 39">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456252" aria-label="PubMed Central reference 39">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Bruton%E2%80%99s%20tyrosine%20kinase%20inhibition%20effectively%20protects%20against%20human%20IgE-mediated%20anaphylaxis&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI138448&amp;volume=130&amp;pages=4759-4770&amp;publication_year=2020&amp;author=Dispenza%2CMC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Crawford, J. J. et al. Discovery of GDC-0853: a potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development. <i>J. Med. Chem.</i> <b>61</b>, 2227–2245 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1021/acs.jmedchem.7b01712" data-track-item_id="10.1021/acs.jmedchem.7b01712" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1021%2Facs.jmedchem.7b01712" aria-label="Article reference 40" data-doi="10.1021/acs.jmedchem.7b01712">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXivFCnt7c%3D" aria-label="CAS reference 40">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29457982" aria-label="PubMed reference 40">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Discovery%20of%20GDC-0853%3A%20a%20potent%2C%20selective%2C%20and%20noncovalent%20Bruton%E2%80%99s%20tyrosine%20kinase%20inhibitor%20in%20early%20clinical%20development&amp;journal=J.%20Med.%20Chem.&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;volume=61&amp;pages=2227-2245&amp;publication_year=2018&amp;author=Crawford%2CJJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Deza, G. et al. Relevance of the basophil high-affinity IgE receptor in chronic urticaria: clinical experience from a tertiary care institution. <i>J. Allergy Clin. Immunol. Pract.</i> <b>7</b>, 1619–1626.e1 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaip.2019.01.026" data-track-item_id="10.1016/j.jaip.2019.01.026" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaip.2019.01.026" aria-label="Article reference 41" data-doi="10.1016/j.jaip.2019.01.026">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30685572" aria-label="PubMed reference 41">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Relevance%20of%20the%20basophil%20high-affinity%20IgE%20receptor%20in%20chronic%20urticaria%3A%20clinical%20experience%20from%20a%20tertiary%20care%20institution&amp;journal=J.%20Allergy%20Clin.%20Immunol.%20Pract.&amp;doi=10.1016%2Fj.jaip.2019.01.026&amp;volume=7&amp;pages=1619-1626.e1&amp;publication_year=2019&amp;author=Deza%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Holowka, D., Sil, D., Torigoe, C. &amp; Baird, B. Insights into immunoglobulin E receptor signaling from structurally defined ligands. <i>Immunol. Rev.</i> <b>217</b>, 269–279 (2007).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/j.1600-065X.2007.00517.x" data-track-item_id="10.1111/j.1600-065X.2007.00517.x" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fj.1600-065X.2007.00517.x" aria-label="Article reference 42" data-doi="10.1111/j.1600-065X.2007.00517.x">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2sXnt1Gmu7w%3D" aria-label="CAS reference 42">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17498065" aria-label="PubMed reference 42">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=Insights%20into%20immunoglobulin%20E%20receptor%20signaling%20from%20structurally%20defined%20ligands&amp;journal=Immunol.%20Rev.&amp;doi=10.1111%2Fj.1600-065X.2007.00517.x&amp;volume=217&amp;pages=269-279&amp;publication_year=2007&amp;author=Holowka%2CD&amp;author=Sil%2CD&amp;author=Torigoe%2CC&amp;author=Baird%2CB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Vonakis, B. M. &amp; Saini, S. S. Syk-deficient basophils from donors with chronic idiopathic urticaria exhibit a spectrum of releasability. <i>J. Allergy Clin. Immunol.</i> <b>121</b>, 262–264 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2007.10.010" data-track-item_id="10.1016/j.jaci.2007.10.010" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2007.10.010" aria-label="Article reference 43" data-doi="10.1016/j.jaci.2007.10.010">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXovVyqug%3D%3D" aria-label="CAS reference 43">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18206515" aria-label="PubMed reference 43">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=Syk-deficient%20basophils%20from%20donors%20with%20chronic%20idiopathic%20urticaria%20exhibit%20a%20spectrum%20of%20releasability&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2007.10.010&amp;volume=121&amp;pages=262-264&amp;publication_year=2008&amp;author=Vonakis%2CBM&amp;author=Saini%2CSS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">Puccetti, A. et al. In chronic idiopathic urticaria autoantibodies against FcɛRII/CD23 induce histamine release via eosinophil activation. <i>Clin. Exp. Allergy</i> <b>35</b>, 1599–1607 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/j.1365-2222.2005.02380.x" data-track-item_id="10.1111/j.1365-2222.2005.02380.x" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fj.1365-2222.2005.02380.x" aria-label="Article reference 44" data-doi="10.1111/j.1365-2222.2005.02380.x">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD28Xnt12rtw%3D%3D" aria-label="CAS reference 44">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16393326" aria-label="PubMed reference 44">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=In%20chronic%20idiopathic%20urticaria%20autoantibodies%20against%20Fc%C9%9BRII%2FCD23%20induce%20histamine%20release%20via%20eosinophil%20activation&amp;journal=Clin.%20Exp.%20Allergy&amp;doi=10.1111%2Fj.1365-2222.2005.02380.x&amp;volume=35&amp;pages=1599-1607&amp;publication_year=2005&amp;author=Puccetti%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">Griffith, Q. K., Liang, Y., Onguru, D. O., Mwinzi, P. N. &amp; Ganley-Leal, L. M. CD23-bound IgE augments and dominates recall responses through human naive B cells. <i>J. Immunol.</i> <b>186</b>, 1060–1067 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4049/jimmunol.1002709" data-track-item_id="10.4049/jimmunol.1002709" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4049%2Fjimmunol.1002709" aria-label="Article reference 45" data-doi="10.4049/jimmunol.1002709">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXjs1Kruw%3D%3D" aria-label="CAS reference 45">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21160045" aria-label="PubMed reference 45">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=CD23-bound%20IgE%20augments%20and%20dominates%20recall%20responses%20through%20human%20naive%20B%20cells&amp;journal=J.%20Immunol.&amp;doi=10.4049%2Fjimmunol.1002709&amp;volume=186&amp;pages=1060-1067&amp;publication_year=2011&amp;author=Griffith%2CQK&amp;author=Liang%2CY&amp;author=Onguru%2CDO&amp;author=Mwinzi%2CPN&amp;author=Ganley-Leal%2CLM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Amanna, I. J., Carlson, N. E. &amp; Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. <i>N. Engl. J. Med.</i> <b>357</b>, 1903–1915 (2007).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa066092" data-track-item_id="10.1056/NEJMoa066092" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa066092" aria-label="Article reference 46" data-doi="10.1056/NEJMoa066092">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2sXht1ymtbjI" aria-label="CAS reference 46">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17989383" aria-label="PubMed reference 46">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=Duration%20of%20humoral%20immunity%20to%20common%20viral%20and%20vaccine%20antigens&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa066092&amp;volume=357&amp;pages=1903-1915&amp;publication_year=2007&amp;author=Amanna%2CIJ&amp;author=Carlson%2CNE&amp;author=Slifka%2CMK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Hibi, T. &amp; Dosch, H. M. Limiting dilution analysis of the B cell compartment in human bone marrow. <i>Eur. J. Immunol.</i> <b>16</b>, 139–145 (1986).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/eji.1830160206" data-track-item_id="10.1002/eji.1830160206" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Feji.1830160206" aria-label="Article reference 47" data-doi="10.1002/eji.1830160206">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DyaL287msVGlsA%3D%3D" aria-label="CAS reference 47">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2869953" aria-label="PubMed reference 47">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=Limiting%20dilution%20analysis%20of%20the%20B%20cell%20compartment%20in%20human%20bone%20marrow&amp;journal=Eur.%20J.%20Immunol.&amp;doi=10.1002%2Feji.1830160206&amp;volume=16&amp;pages=139-145&amp;publication_year=1986&amp;author=Hibi%2CT&amp;author=Dosch%2CHM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Smith, C. I. et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. <i>J. Immunol.</i> <b>152</b>, 557–565 (1994).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4049/jimmunol.152.2.557" data-track-item_id="10.4049/jimmunol.152.2.557" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4049%2Fjimmunol.152.2.557" aria-label="Article reference 48" data-doi="10.4049/jimmunol.152.2.557">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK2cXhtVCrsb0%3D" aria-label="CAS reference 48">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8283037" aria-label="PubMed reference 48">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=Expression%20of%20Bruton%E2%80%99s%20agammaglobulinemia%20tyrosine%20kinase%20gene%2C%20BTK%2C%20is%20selectively%20down-regulated%20in%20T%20lymphocytes%20and%20plasma%20cells&amp;journal=J.%20Immunol.&amp;doi=10.4049%2Fjimmunol.152.2.557&amp;volume=152&amp;pages=557-565&amp;publication_year=1994&amp;author=Smith%2CCI">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="49."><p class="c-article-references__text" id="ref-CR49">Katewa, A. et al. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis. <i>JCI Insight</i> <b>2</b>, e90111 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1172/jci.insight.90111" data-track-item_id="10.1172/jci.insight.90111" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1172%2Fjci.insight.90111" aria-label="Article reference 49" data-doi="10.1172/jci.insight.90111">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28405610" aria-label="PubMed reference 49">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374071" aria-label="PubMed Central reference 49">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=Btk-specific%20inhibition%20blocks%20pathogenic%20plasma%20cell%20signatures%20and%20myeloid%20cell-associated%20damage%20in%20IFN%CE%B1-driven%20lupus%20nephritis&amp;journal=JCI%20Insight&amp;doi=10.1172%2Fjci.insight.90111&amp;volume=2&amp;publication_year=2017&amp;author=Katewa%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="50."><p class="c-article-references__text" id="ref-CR50">Montalban, X. et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. <i>N. Engl. J. Med.</i> <b>380</b>, 2406–2417 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1901981" data-track-item_id="10.1056/NEJMoa1901981" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1901981" aria-label="Article reference 50" data-doi="10.1056/NEJMoa1901981">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXnsFGqurs%3D" aria-label="CAS reference 50">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31075187" aria-label="PubMed reference 50">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=Placebo-controlled%20trial%20of%20an%20oral%20BTK%20inhibitor%20in%20multiple%20sclerosis&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1901981&amp;volume=380&amp;pages=2406-2417&amp;publication_year=2019&amp;author=Montalban%2CX">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="51."><p class="c-article-references__text" id="ref-CR51">Atallah, E. et al. Zanubrutinib-induced liver injury: a case report and literature review. <i>BMC Gastroenterol.</i> <b>21</b>, 244 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s12876-021-01825-2" data-track-item_id="10.1186/s12876-021-01825-2" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s12876-021-01825-2" aria-label="Article reference 51" data-doi="10.1186/s12876-021-01825-2">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34051727" aria-label="PubMed reference 51">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164809" aria-label="PubMed Central reference 51">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 51" href="http://scholar.google.com/scholar_lookup?&amp;title=Zanubrutinib-induced%20liver%20injury%3A%20a%20case%20report%20and%20literature%20review&amp;journal=BMC%20Gastroenterol.&amp;doi=10.1186%2Fs12876-021-01825-2&amp;volume=21&amp;publication_year=2021&amp;author=Atallah%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="52."><p class="c-article-references__text" id="ref-CR52">Kaplan, A. et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. <i>J. Allergy Clin. Immunol.</i> <b>132</b>, 101–109 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jaci.2013.05.013" data-track-item_id="10.1016/j.jaci.2013.05.013" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jaci.2013.05.013" aria-label="Article reference 52" data-doi="10.1016/j.jaci.2013.05.013">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtVWlsbzF" aria-label="CAS reference 52">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23810097" aria-label="PubMed reference 52">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 52" href="http://scholar.google.com/scholar_lookup?&amp;title=Omalizumab%20in%20patients%20with%20symptomatic%20chronic%20idiopathic%2Fspontaneous%20urticaria%20despite%20standard%20combination%20therapy&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2013.05.013&amp;volume=132&amp;pages=101-109&amp;publication_year=2013&amp;author=Kaplan%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="53."><p class="c-article-references__text" id="ref-CR53">Maurer, M. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. <i>N. Engl. J. Med.</i> <b>368</b>, 924–935 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1215372" data-track-item_id="10.1056/NEJMoa1215372" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1215372" aria-label="Article reference 53" data-doi="10.1056/NEJMoa1215372">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXjvFChsrk%3D" aria-label="CAS reference 53">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23432142" aria-label="PubMed reference 53">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 53" href="http://scholar.google.com/scholar_lookup?&amp;title=Omalizumab%20for%20the%20treatment%20of%20chronic%20idiopathic%20or%20spontaneous%20urticaria&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1215372&amp;volume=368&amp;pages=924-935&amp;publication_year=2013&amp;author=Maurer%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="54."><p class="c-article-references__text" id="ref-CR54">Saini, S. S. et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H<sub>1</sub> antihistamines: a randomized, placebo-controlled study. <i>J. Invest. Dermatol.</i> <b>135</b>, 67–75 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/jid.2014.306" data-track-item_id="10.1038/jid.2014.306" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fjid.2014.306" aria-label="Article reference 54" data-doi="10.1038/jid.2014.306">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25046337" aria-label="PubMed reference 54">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 54" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20and%20safety%20of%20omalizumab%20in%20patients%20with%20chronic%20idiopathic%2Fspontaneous%20urticaria%20who%20remain%20symptomatic%20on%20H1%20antihistamines%3A%20a%20randomized%2C%20placebo-controlled%20study&amp;journal=J.%20Invest.%20Dermatol.&amp;doi=10.1038%2Fjid.2014.306&amp;volume=135&amp;pages=67-75&amp;publication_year=2015&amp;author=Saini%2CSS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="55."><p class="c-article-references__text" id="ref-CR55">Kulthanan, K. et al. Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). <i>Health Qual. Life Outcomes</i> <b>14</b>, 61 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s12955-016-0466-y" data-track-item_id="10.1186/s12955-016-0466-y" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s12955-016-0466-y" aria-label="Article reference 55" data-doi="10.1186/s12955-016-0466-y">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27075142" aria-label="PubMed reference 55">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831163" aria-label="PubMed Central reference 55">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 55" href="http://scholar.google.com/scholar_lookup?&amp;title=Validity%2C%20reliability%20and%20interpretability%20of%20the%20Thai%20version%20of%20the%20urticaria%20control%20test%20%28UCT%29&amp;journal=Health%20Qual.%20Life%20Outcomes&amp;doi=10.1186%2Fs12955-016-0466-y&amp;volume=14&amp;publication_year=2016&amp;author=Kulthanan%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="56."><p class="c-article-references__text" id="ref-CR56">Mathias, S. D., Crosby, R. D., Zazzali, J. L., Maurer, M. &amp; Saini, S. S. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. <i>Ann. Allergy Asthma Immunol.</i> <b>108</b>, 20–24 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.anai.2011.09.008" data-track-item_id="10.1016/j.anai.2011.09.008" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.anai.2011.09.008" aria-label="Article reference 56" data-doi="10.1016/j.anai.2011.09.008">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22192960" aria-label="PubMed reference 56">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=Evaluating%20the%20minimally%20important%20difference%20of%20the%20urticaria%20activity%20score%20and%20other%20measures%20of%20disease%20activity%20in%20patients%20with%20chronic%20idiopathic%20urticaria&amp;journal=Ann.%20Allergy%20Asthma%20Immunol.&amp;doi=10.1016%2Fj.anai.2011.09.008&amp;volume=108&amp;pages=20-24&amp;publication_year=2012&amp;author=Mathias%2CSD&amp;author=Crosby%2CRD&amp;author=Zazzali%2CJL&amp;author=Maurer%2CM&amp;author=Saini%2CSS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="57."><p class="c-article-references__text" id="ref-CR57">O’Kelly, M. &amp; Ratitch, B. <i>Clinical Trials with Missing Data: a Guide for Practitioners</i> (John Wiley &amp; Sons, 2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/9781118762516" data-track-item_id="10.1002/9781118762516" data-track-value="book reference" data-track-action="book reference" href="https://doi.org/10.1002%2F9781118762516" aria-label="Book reference 57" data-doi="10.1002/9781118762516">Book</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 57" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20Trials%20with%20Missing%20Data%3A%20a%20Guide%20for%20Practitioners&amp;doi=10.1002%2F9781118762516&amp;publication_year=2014&amp;author=O%E2%80%99Kelly%2CM&amp;author=Ratitch%2CB">
                    Google Scholar</a>&nbsp;
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01537-w?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>This trial was supported by Genentech. Genentech was involved in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review and approval of the manuscript and decision to submit the manuscript for publication. We thank the patients and their families who participated in this trial. We also thank S. Limb and D. Musselman for their expertise and assistance throughout the study, as well as the investigators, healthcare providers and the staff who conducted the study. Editing and writing assistance was provided by D. Solymar (Genentech) and was funded by Genentech.</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany</p><p class="c-article-author-affiliation__authors-list">Martin Metz&nbsp;&amp;&nbsp;Marcus Maurer</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany</p><p class="c-article-author-affiliation__authors-list">Martin Metz&nbsp;&amp;&nbsp;Marcus Maurer</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Division of Allergy and Clinical Immunology, St. Michael’s Hospital and University of Toronto, Toronto, Ontario, Canada</p><p class="c-article-author-affiliation__authors-list">Gordon Sussman</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Service d’Allergie et Immunologie, Département de Médecine, Centre Hospitalier Universitaire de Québec, Quebec City, Québec, Canada</p><p class="c-article-author-affiliation__authors-list">Rémi Gagnon</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">Department of Dermatology, University Medical Center Mainz, Mainz, Germany</p><p class="c-article-author-affiliation__authors-list">Petra Staubach</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Kern Allergy Medical Clinic Inc., Bakersfield, CA, USA</p><p class="c-article-author-affiliation__authors-list">Tonny Tanus</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada</p><p class="c-article-author-affiliation__authors-list">William H. Yang</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Genentech, Inc., South San Francisco, CA, USA</p><p class="c-article-author-affiliation__authors-list">Jeremy J. Lim,&nbsp;Holly J. Clarke,&nbsp;Joshua Galanter,&nbsp;Leslie W. Chinn,&nbsp;Tom Chu,&nbsp;Tracy Burgess,&nbsp;D. James Haddon&nbsp;&amp;&nbsp;Timothy T. Lu</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Hoffman-LaRoche Limited, Missisauga, Ontario, Canada</p><p class="c-article-author-affiliation__authors-list">Anastasia Teterina</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Martin-Metz-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Martin Metz</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Martin%20Metz" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Martin%20Metz" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Martin%20Metz%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Gordon-Sussman-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Gordon Sussman</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Gordon%20Sussman" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Gordon%20Sussman" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Gordon%20Sussman%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-R_mi-Gagnon-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Rémi Gagnon</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=R%C3%A9mi%20Gagnon" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=R%C3%A9mi%20Gagnon" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22R%C3%A9mi%20Gagnon%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Petra-Staubach-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Petra Staubach</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Petra%20Staubach" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Petra%20Staubach" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Petra%20Staubach%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Tonny-Tanus-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Tonny Tanus</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Tonny%20Tanus" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Tonny%20Tanus" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Tonny%20Tanus%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-William_H_-Yang-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">William H. Yang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=William%20H.%20Yang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=William%20H.%20Yang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22William%20H.%20Yang%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jeremy_J_-Lim-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Jeremy J. Lim</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jeremy%20J.%20Lim" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jeremy%20J.%20Lim" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jeremy%20J.%20Lim%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Holly_J_-Clarke-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Holly J. Clarke</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Holly%20J.%20Clarke" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Holly%20J.%20Clarke" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Holly%20J.%20Clarke%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Joshua-Galanter-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Joshua Galanter</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Joshua%20Galanter" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Joshua%20Galanter" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Joshua%20Galanter%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Leslie_W_-Chinn-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Leslie W. Chinn</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Leslie%20W.%20Chinn" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Leslie%20W.%20Chinn" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Leslie%20W.%20Chinn%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Tom-Chu-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Tom Chu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Tom%20Chu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Tom%20Chu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Tom%20Chu%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Anastasia-Teterina-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Anastasia Teterina</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Anastasia%20Teterina" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Anastasia%20Teterina" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Anastasia%20Teterina%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Tracy-Burgess-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Tracy Burgess</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Tracy%20Burgess" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Tracy%20Burgess" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Tracy%20Burgess%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-D__James-Haddon-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">D. James Haddon</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=D.%20James%20Haddon" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=D.%20James%20Haddon" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22D.%20James%20Haddon%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Timothy_T_-Lu-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Timothy T. Lu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Timothy%20T.%20Lu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Timothy%20T.%20Lu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Timothy%20T.%20Lu%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Marcus-Maurer-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Marcus Maurer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Marcus%20Maurer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Marcus%20Maurer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Marcus%20Maurer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>M. Maurer had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. M. Metz, G.S., H.J.C., L.W.C., T.C., T.B., D.J.H., T.T.L. and M. Maurer conceived and designed the study. M. Metz, G.S., R.G., P.S., T.T., W.H.Y., J.J.L., H.J.C., T.B., D.J.H., T.T.L. and M. Maurer acquired the data. M. Metz, G.S., R.G., W.H.Y., J.J.L., H.J.C., J.G., L.W.C., T.C., A.T., T.B., D.J.H., T.T.L. and M. Maurer analyzed or interpreted the data. M. Metz, G.S., R.G., W.H.Y., J.J.L., H.J.C., J.G., L.W.C., T.C., A.T., D.J.H., T.T.L. and M. Maurer drafted the manuscript. M. Metz, G.S., R.G., P.S., T.T., W.H.Y., J.J.L., J.G., L.W.C., T.C., A.T., T.B., D.J.H., T.T.L. and M. Maurer critically revised the manuscript for important intellectual content.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:marcus.maurer@charite.de">Marcus Maurer</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar3">Competing interests</h3>
                <p>M. Metz reports receiving honoraria as a speaker and/or consultant for Amgen, Aralez, argenx, Moxie, Novartis, Roche, Sanofi, Shire and Uriach. G.S. reports serving as a principal investigator for Genentech, Novartis, CSL Behring, Shire, Sanofi, AstraZeneca, DBV Technologies, Aimmune Therapeutics, Greencross, Kedrion, ALK-Abelló, Stallergenes, LEO Pharma, Amgen, BioCryst, Regeneron and Cliantha; serving on advisory boards for Novartis, CSL Behring, Shire, Sanofi, Aralez, Pediapharm and AstraZeneca; serving as a speaker for Novartis, Sanofi, Aralez, Pediapharm, Genentech and AstraZeneca; receiving personal fees from Novartis, CSL Behring, Shire, Sanofi, Aralez, Pediapharm and AstraZeneca. T.T. reports receiving funding from Genentech to his institution for the conduct of this study. W.H.Y. reports receiving speakers’ fees from Novartis, Merck, CSL Behring, Takeda (Shire) and AstraZeneca; serving on advisory boards for Novartis, Takeda (Shire), CSL Behring, Sanofi, BioCryst and Merck; and receiving research grants from Novartis, Takeda (Shire), CSL Behring, BioCryst, AstraZeneca, Regeneron, Sanofi, Genentech, Glenmark, AnaptysBio, Dermira, Galderma, ALK, DBV Technologies, Aimmune Therapeutics, Colgene and Pharming. J.J.L., H.J.C., J.G., L.W.C., T.C., T.B., D.J.H. and T.T.L. are current or former employees of Genentech, a member of the Roche group, at the time this work was performed and own/owned Roche stock and/or options. L.W.C. is currently an employee of Principia Biopharma and owns Principia Biopharma stock and/or options. D.J.H. owns Principia Biopharma stock. T.T.L. is currently an employee of DiCE Molecules. M. Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Amgen, Aralez, AstraZeneca, Celldex, Centogene, CSL Behring, FAES, Genentech, GI Innovation, Innate Pharma, Kyowa Kirin, LEO Pharma, Lilly, Menarini, Moxie, Merck Sharp &amp; Dohme, Novartis, Roche, Sanofi/Regeneron, Third Harmonic Bio, UCB and Uriach. R.G. and P.S. declare no competing interests.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Peer review information</b> <i>Nature Medicine</i> thanks Brian Kim, Michael Grayling, Allen Kaplan and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Saheli Sadanand was the primary handling editor, in collaboration with the <i>Nature Medicine</i> team.</p><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec22-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec22">Extended data</h2><div class="c-article-section__content" id="Sec22-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig4"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 study design." href="/articles/s41591-021-01537-w/figures/4" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig4_ESM.jpg">Extended Data Fig. 1 Study design.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Study design.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig5"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 study flow in cohort 1." href="/articles/s41591-021-01537-w/figures/5" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig5_ESM.jpg">Extended Data Fig. 2 Study flow in cohort 1.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Study flow in cohort 1.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 complete responders in cohort" href="/articles/s41591-021-01537-w/figures/6" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig6_ESM.jpg">Extended Data Fig. 3 Complete responders in Cohort 2.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Proportion of patients who were complete responders in Cohort 2.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 time to mid in uas7 score." href="/articles/s41591-021-01537-w/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig7_ESM.jpg">Extended Data Fig. 4 Time to MID in UAS7 score.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Time to MID (Kaplan-Meier estimate) in UAS7 score (modified intention-to-treat population). (<b>a</b>) Cohort 2. (<b>b</b>) Cohort 1.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 uas7 at week 8." href="/articles/s41591-021-01537-w/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig8_ESM.jpg">Extended Data Fig. 5 UAS7 at Week 8.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>UAS7 at Week 8 in all patients and patients stratified by (a) BHRA and (b) IgE in Cohort 2. Stratification by IgG-anti-FcεRI was not performed due to small sample size.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 uas7 stratified by (a) bhra, " href="/articles/s41591-021-01537-w/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig9_ESM.jpg">Extended Data Fig. 6 UAS7 stratified by (a) BHRA, (b) IgG-anti-FcεRI, and (c) IgE concentrations in Cohort 1.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>UAS7 stratified by (<b>a</b>) BHRA, (<b>b</b>) IgG-anti-FcεRI, and (<b>c</b>) IgE concentrations in Cohort 1. Thin lines, individual patients. Thick lines, means. Blue shaded area, follow-up period.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 uas7 at week 8 in all patient" href="/articles/s41591-021-01537-w/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig10_ESM.jpg">Extended Data Fig. 7 UAS7 at Week 8 in all patients and patients stratified by (a) BHRA and (b) IgE in Cohort 1.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>UAS7 at Week 8 in all patients and patients stratified by (a) BHRA and (b) IgE in Cohort 1. Stratification by IgG-anti-FcεRI was not performed due to small sample size.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 8 change in total serum concent" href="/articles/s41591-021-01537-w/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig11_ESM.jpg">Extended Data Fig. 8 Change in total serum concentrations of immunoglobulin subclasses during the treatment period in Cohort 1.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Change in total serum concentrations of immunoglobulin subclasses during the treatment period in Cohort 1. Thin lines, individual patients; thick blue lines, means.</p></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec23-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec23">Supplementary information</h2><div class="c-article-section__content" id="Sec23-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary information" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_MOESM1_ESM.pdf" data-supp-info-image="">Supplementary Information</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>List of IRBs, supplementary results, biomarker analysis plan, original protocol, final protocols and summary of protocol amendments.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_MOESM2_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Fenebrutinib%20in%20H1%20antihistamine-refractory%20chronic%20spontaneous%20urticaria%3A%20a%20randomized%20phase%202%20trial&amp;author=Martin%20Metz%20et%20al&amp;contentID=10.1038%2Fs41591-021-01537-w&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2021-11-08&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-021-01537-w" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-021-01537-w" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Metz, M., Sussman, G., Gagnon, R. <i>et al.</i> Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.
                    <i>Nat Med</i> <b>27</b>, 1961–1969 (2021). https://doi.org/10.1038/s41591-021-01537-w</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01537-w?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-02-19">19 February 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-09-10">10 September 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-11-08">08 November 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-11">November 2021</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-021-01537-w</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/immunological-disorders" data-track="click" data-track-action="view subject" data-track-label="link">Immunological disorders</a></li><li class="c-article-subject-list__subject"><a href="/subjects/mast-cells" data-track="click" data-track-action="view subject" data-track-label="link">Mast cells</a></li><li class="c-article-subject-list__subject"><a href="/subjects/randomized-controlled-trials" data-track="click" data-track-action="view subject" data-track-label="link">Randomized controlled trials</a></li><li class="c-article-subject-list__subject"><a href="/subjects/skin-manifestations" data-track="click" data-track-action="view subject" data-track-label="link">Skin manifestations</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Update on the Treatment of Chronic Spontaneous Urticaria" href="https://doi.org/10.1007/s40265-025-02170-4">
                                        Update on the Treatment of Chronic Spontaneous Urticaria
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Pavel Kolkhir</li><li>Jie Shen Fok</li><li>Martin Metz</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Drugs</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered?" href="https://doi.org/10.1007/s40272-024-00675-1">
                                        Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered?
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Rabporn Suntornlohanakul</li><li>E. Ann Yeh</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Pediatric Drugs</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments" href="https://doi.org/10.1186/s42358-024-00401-y">
                                        Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Gita Manzari Tavakoli</li><li>Niloufar Yazdanpanah</li><li>Nima Rezaei</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Advances in Rheumatology</i> (2024)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Krankheitsaktivität und Therapie regelmäßig reevaluieren" href="https://doi.org/10.1007/s15011-024-6493-9">
                                        Krankheitsaktivität und Therapie regelmäßig reevaluieren
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Susanne Melchers</li><li>Jan P. Nicolay</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Deutsche Dermatologie</i> (2024)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:The Effect of Placebo on Pruritus in Patients with Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials" href="https://doi.org/10.1007/s40261-024-01389-5">
                                        The Effect of Placebo on Pruritus in Patients with Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Peiwen Xue</li><li>Haiyan Qin</li><li>Xianjun Xiao</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Clinical Drug Investigation</i> (2024)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01537-w.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: 409.45px;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec10" class="c-reading-companion__section-item"><a href="#Sec10" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec11" class="c-reading-companion__section-item"><a href="#Sec11" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec22" class="c-reading-companion__section-item"><a href="#Sec22" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec23" class="c-reading-companion__section-item"><a href="#Sec23" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-021-01537-w;doi=10.1038/s41591-021-01537-w;subjmeta=1630,1807,1812,223,249,250,2504,2779,308,631,692,699,777;kwrd=Immunological+disorders,Mast+cells,Randomized+controlled+trials,Skin+manifestations">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=1878314569&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-021-01537-w%26doi%3D10.1038/s41591-021-01537-w%26subjmeta%3D1630,1807,1812,223,249,250,2504,2779,308,631,692,699,777%26kwrd%3DImmunological+disorders,Mast+cells,Randomized+controlled+trials,Skin+manifestations">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=1878314569&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-021-01537-w%26doi%3D10.1038/s41591-021-01537-w%26subjmeta%3D1630,1807,1812,223,249,250,2504,2779,308,631,692,699,777%26kwrd%3DImmunological+disorders,Mast+cells,Randomized+controlled+trials,Skin+manifestations"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2: Effects of fenebrutinib on the UAS7, UAS7 components and proportion of well-controlled responders.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3: Effects of fenebrutinib on markers of type IIb autoimmunity.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Extended Data Fig. 1 Study design.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig4_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig4_ESM.jpg" alt="extended data figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Extended Data Fig. 2 Study flow in cohort 1.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig5_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig5_ESM.jpg" alt="extended data figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Extended Data Fig. 3 Complete responders in Cohort 2.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig6_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig6_ESM.jpg" alt="extended data figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 4 Time to MID in UAS7 score.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 5 UAS7 at Week 8.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig9">Extended Data Fig. 6 UAS7 stratified by (a) BHRA, (b) IgG-anti-FcεRI, and (c) IgE concentrations in Cohort 1.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig9_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig9_ESM.jpg" alt="extended data figure 9" aria-describedby="rc-Fig9"></picture><p class="c-reading-companion__figure-links"><a href="#Fig9" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/9" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig10">Extended Data Fig. 7 UAS7 at Week 8 in all patients and patients stratified by (a) BHRA and (b) IgE in Cohort 1.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig10_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig10_ESM.jpg" alt="extended data figure 10" aria-describedby="rc-Fig10"></picture><p class="c-reading-companion__figure-links"><a href="#Fig10" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/10" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig11">Extended Data Fig. 8 Change in total serum concentrations of immunoglobulin subclasses during the treatment period in Cohort 1.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig11_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01537-w/MediaObjects/41591_2021_1537_Fig11_ESM.jpg" alt="extended data figure 11" aria-describedby="rc-Fig11"></picture><p class="c-reading-companion__figure-links"><a href="#Fig11" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01537-w/figures/11" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Zuberbier, T. et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy</i> <b>73</b>, 1393–1414 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fall.13397" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/all.13397" data-track-item_id="10.1111/all.13397">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC1MvgvFeqsA%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29336054" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20EAACI%2FGA%C2%B2LEN%2FEDF%2FWAO%20guideline%20for%20the%20definition%2C%20classification%2C%20diagnosis%20and%20management%20of%20urticaria&amp;journal=Allergy&amp;doi=10.1111%2Fall.13397&amp;volume=73&amp;pages=1393-1414&amp;publication_year=2018&amp;author=Zuberbier%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Fricke, J. et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. <i>Allergy</i> <b>75</b>, 423–432 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fall.14037" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/all.14037" data-track-item_id="10.1111/all.14037">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31494963" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Prevalence%20of%20chronic%20urticaria%20in%20children%20and%20adults%20across%20the%20globe%3A%20systematic%20review%20with%20meta-analysis&amp;journal=Allergy&amp;doi=10.1111%2Fall.14037&amp;volume=75&amp;pages=423-432&amp;publication_year=2020&amp;author=Fricke%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">Kolkhir, P. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. <i>J. Allergy Clin. Immunol.</i> <b>139</b>, 1772–1781.e1 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2016.08.050" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2016.08.050" data-track-item_id="10.1016/j.jaci.2016.08.050">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhvFKnsbfJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27777182" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Autoimmune%20chronic%20spontaneous%20urticaria%3A%20what%20we%20know%20and%20what%20we%20do%20not%20know&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2016.08.050&amp;volume=139&amp;pages=1772-1781.e1&amp;publication_year=2017&amp;author=Kolkhir%2CP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">Schmetzer, O. et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. <i>J. Allergy Clin. Immunol.</i> <b>142</b>, 876–882 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2017.10.035" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2017.10.035" data-track-item_id="10.1016/j.jaci.2017.10.035">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXjvFGqtQ%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29208545" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=IL-24%20is%20a%20common%20and%20specific%20autoantigen%20of%20IgE%20in%20patients%20with%20chronic%20spontaneous%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2017.10.035&amp;volume=142&amp;pages=876-882&amp;publication_year=2018&amp;author=Schmetzer%2CO" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Niu, X. L. et al. Association of positive and negative autologous serum skin test responses with clinical features of chronic spontaneous urticaria in Asian patients: a systematic review and meta-analysis. <i>Exp. Ther. Med.</i> <b>17</b>, 2603–2613 (2019).</p><p class="c-reading-companion__reference-links"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30906452" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425266" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20of%20positive%20and%20negative%20autologous%20serum%20skin%20test%20responses%20with%20clinical%20features%20of%20chronic%20spontaneous%20urticaria%20in%20Asian%20patients%3A%20a%20systematic%20review%20and%20meta-analysis&amp;journal=Exp.%20Ther.%20Med.&amp;volume=17&amp;pages=2603-2613&amp;publication_year=2019&amp;author=Niu%2CXL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Altrichter, S. et al. Total IgE as a marker for chronic spontaneous urticaria. <i>Allergy Asthma Immunol. Res.</i> <b>13</b>, 206–218 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4168%2Faair.2021.13.2.206" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4168/aair.2021.13.2.206" data-track-item_id="10.4168/aair.2021.13.2.206">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsFWiu7%2FN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33474856" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840871" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Total%20IgE%20as%20a%20marker%20for%20chronic%20spontaneous%20urticaria&amp;journal=Allergy%20Asthma%20Immunol.%20Res.&amp;doi=10.4168%2Faair.2021.13.2.206&amp;volume=13&amp;pages=206-218&amp;publication_year=2021&amp;author=Altrichter%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Altrichter, S. et al. IgE mediated autoallergy against thyroid peroxidase––a novel pathomechanism of chronic spontaneous urticaria? <i>PLoS ONE</i> <b>6</b>, e14794 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pone.0014794" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pone.0014794" data-track-item_id="10.1371/journal.pone.0014794">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXltV2mtb0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21532759" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075251" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=IgE%20mediated%20autoallergy%20against%20thyroid%20peroxidase%E2%80%93%E2%80%93a%20novel%20pathomechanism%20of%20chronic%20spontaneous%20urticaria%3F&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0014794&amp;volume=6&amp;publication_year=2011&amp;author=Altrichter%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Maurer, M. et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. <i>J. Allergy Clin. Immunol.</i> <b>128</b>, 202–209.e5 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2011.04.038" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2011.04.038" data-track-item_id="10.1016/j.jaci.2011.04.038">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXosFakurk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21636116" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20and%20safety%20of%20omalizumab%20in%20patients%20with%20chronic%20urticaria%20who%20exhibit%20IgE%20against%20thyroperoxidase&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2011.04.038&amp;volume=128&amp;pages=202-209.e5&amp;publication_year=2011&amp;author=Maurer%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Lakin, E., Church, M. K., Maurer, M. &amp; Schmetzer, O. On the lipophilic nature of autoreactive IgE in chronic spontaneous urticaria. <i>Theranostics</i> <b>9</b>, 829–836 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.7150%2Fthno.29902" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.7150/thno.29902" data-track-item_id="10.7150/thno.29902">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtlGqsrrN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30809311" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376472" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=On%20the%20lipophilic%20nature%20of%20autoreactive%20IgE%20in%20chronic%20spontaneous%20urticaria&amp;journal=Theranostics&amp;doi=10.7150%2Fthno.29902&amp;volume=9&amp;pages=829-836&amp;publication_year=2019&amp;author=Lakin%2CE&amp;author=Church%2CMK&amp;author=Maurer%2CM&amp;author=Schmetzer%2CO" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Asero, R. et al. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. <i>Clin. Exp. Immunol.</i> <b>200</b>, 242–249 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fcei.13428" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/cei.13428" data-track-item_id="10.1111/cei.13428">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXpsFOhurg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32115683" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231996" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Co-occurrence%20of%20IgE%20and%20IgG%20autoantibodies%20in%20patients%20with%20chronic%20spontaneous%20urticaria&amp;journal=Clin.%20Exp.%20Immunol.&amp;doi=10.1111%2Fcei.13428&amp;volume=200&amp;pages=242-249&amp;publication_year=2020&amp;author=Asero%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Hide, M. et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. <i>N. Engl. J. Med.</i> <b>328</b>, 1599–1604 (1993).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJM199306033282204" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJM199306033282204" data-track-item_id="10.1056/NEJM199306033282204">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DyaK3s3lsVGjsw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=7683772" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Autoantibodies%20against%20the%20high-affinity%20IgE%20receptor%20as%20a%20cause%20of%20histamine%20release%20in%20chronic%20urticaria&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJM199306033282204&amp;volume=328&amp;pages=1599-1604&amp;publication_year=1993&amp;author=Hide%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">Sánchez, J., Sánchez, A. &amp; Cardona, R. Causal relationship between anti-TPO IgE and chronic urticaria by in vitro and in vivo tests. <i>Allergy Asthma Immunol. Res.</i> <b>11</b>, 29–42 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4168%2Faair.2019.11.1.29" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4168/aair.2019.11.1.29" data-track-item_id="10.4168/aair.2019.11.1.29">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30479075" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Causal%20relationship%20between%20anti-TPO%20IgE%20and%20chronic%20urticaria%20by%20in%20vitro%20and%20in%20vivo%20tests&amp;journal=Allergy%20Asthma%20Immunol.%20Res.&amp;doi=10.4168%2Faair.2019.11.1.29&amp;volume=11&amp;pages=29-42&amp;publication_year=2019&amp;author=S%C3%A1nchez%2CJ&amp;author=S%C3%A1nchez%2CA&amp;author=Cardona%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Gruber, B. L., Baeza, M. L., Marchese, M. J., Agnello, V. &amp; Kaplan, A. P. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. <i>J. Invest. Dermatol.</i> <b>90</b>, 213–217 (1988).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2F1523-1747.ep12462239" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/1523-1747.ep12462239" data-track-item_id="10.1111/1523-1747.ep12462239">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DyaL1c7hs1yisw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2448392" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Prevalence%20and%20functional%20role%20of%20anti-IgE%20autoantibodies%20in%20urticarial%20syndromes&amp;journal=J.%20Invest.%20Dermatol.&amp;doi=10.1111%2F1523-1747.ep12462239&amp;volume=90&amp;pages=213-217&amp;publication_year=1988&amp;author=Gruber%2CBL&amp;author=Baeza%2CML&amp;author=Marchese%2CMJ&amp;author=Agnello%2CV&amp;author=Kaplan%2CAP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Grattan, C. E., Francis, D. M., Hide, M. &amp; Greaves, M. W. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. <i>Clin. Exp. Allergy</i> <b>21</b>, 695–704 (1991).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fj.1365-2222.1991.tb03198.x" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/j.1365-2222.1991.tb03198.x" data-track-item_id="10.1111/j.1365-2222.1991.tb03198.x">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DyaK387js1WlsA%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=1723343" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Detection%20of%20circulating%20histamine%20releasing%20autoantibodies%20with%20functional%20properties%20of%20anti-IgE%20in%20chronic%20urticaria&amp;journal=Clin.%20Exp.%20Allergy&amp;doi=10.1111%2Fj.1365-2222.1991.tb03198.x&amp;volume=21&amp;pages=695-704&amp;publication_year=1991&amp;author=Grattan%2CCE&amp;author=Francis%2CDM&amp;author=Hide%2CM&amp;author=Greaves%2CMW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">Niimi, N. et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. <i>J. Invest. Dermatol.</i> <b>106</b>, 1001–1006 (1996).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2F1523-1747.ep12338544" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/1523-1747.ep12338544" data-track-item_id="10.1111/1523-1747.ep12338544">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK28Xjs1Shtb8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8618029" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Dermal%20mast%20cell%20activation%20by%20autoantibodies%20against%20the%20high%20affinity%20IgE%20receptor%20in%20chronic%20urticaria&amp;journal=J.%20Invest.%20Dermatol.&amp;doi=10.1111%2F1523-1747.ep12338544&amp;volume=106&amp;pages=1001-1006&amp;publication_year=1996&amp;author=Niimi%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Kikuchi, Y. &amp; Kaplan, A. P. Mechanism of autoimmune activation of basophils in chronic urticaria. <i>J. Allergy Clin. Immunol.</i> <b>107</b>, 1056–1062 (2001).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1067%2Fmai.2001.115484" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1067/mai.2001.115484" data-track-item_id="10.1067/mai.2001.115484">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD3MXkvFelsLw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11398085" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Mechanism%20of%20autoimmune%20activation%20of%20basophils%20in%20chronic%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1067%2Fmai.2001.115484&amp;volume=107&amp;pages=1056-1062&amp;publication_year=2001&amp;author=Kikuchi%2CY&amp;author=Kaplan%2CAP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">Kikuchi, Y. &amp; Kaplan, A. P. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. <i>J. Allergy Clin. Immunol.</i> <b>109</b>, 114–118 (2002).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1067%2Fmai.2002.120954" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1067/mai.2002.120954" data-track-item_id="10.1067/mai.2002.120954">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38XhsVWltr4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11799375" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20role%20for%20C5a%20in%20augmenting%20IgG-dependent%20histamine%20release%20from%20basophils%20in%20chronic%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1067%2Fmai.2002.120954&amp;volume=109&amp;pages=114-118&amp;publication_year=2002&amp;author=Kikuchi%2CY&amp;author=Kaplan%2CAP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Kaplan, A. P. Chronic spontaneous urticaria: pathogenesis and treatment considerations. <i>Allergy Asthma Immunol. Res.</i> <b>9</b>, 477–482 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4168%2Faair.2017.9.6.477" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4168/aair.2017.9.6.477" data-track-item_id="10.4168/aair.2017.9.6.477">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXksVCitLk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28913986" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603475" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Chronic%20spontaneous%20urticaria%3A%20pathogenesis%20and%20treatment%20considerations&amp;journal=Allergy%20Asthma%20Immunol.%20Res.&amp;doi=10.4168%2Faair.2017.9.6.477&amp;volume=9&amp;pages=477-482&amp;publication_year=2017&amp;author=Kaplan%2CAP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Kaplan, A. et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. <i>J. Allergy Clin. Immunol.</i> <b>137</b>, 474–481 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2015.08.023" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2015.08.023" data-track-item_id="10.1016/j.jaci.2015.08.023">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhs1yjsLzJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26483177" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Timing%20and%20duration%20of%20omalizumab%20response%20in%20patients%20with%20chronic%20idiopathic%2Fspontaneous%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2015.08.023&amp;volume=137&amp;pages=474-481&amp;publication_year=2016&amp;author=Kaplan%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Maurer, M. et al. Ligelizumab for chronic spontaneous urticaria. <i>N. Engl. J. Med.</i> <b>381</b>, 1321–1332 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1900408" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1900408" data-track-item_id="10.1056/NEJMoa1900408">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXnsFCmu7c%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31577874" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Ligelizumab%20for%20chronic%20spontaneous%20urticaria&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1900408&amp;volume=381&amp;pages=1321-1332&amp;publication_year=2019&amp;author=Maurer%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Zweiman, B., Valenzano, M., Atkins, P. C., Tanus, T. &amp; Getsy, J. A. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. <i>J. Allergy Clin. Immunol.</i> <b>98</b>, 89–98 (1996).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS0091-6749%2896%2970230-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S0091-6749(96)70230-0" data-track-item_id="10.1016/S0091-6749(96)70230-0">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK28Xlt1ehs7k%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8765822" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Characteristics%20of%20histamine-releasing%20activity%20in%20the%20sera%20of%20patients%20with%20chronic%20idiopathic%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2FS0091-6749%2896%2970230-0&amp;volume=98&amp;pages=89-98&amp;publication_year=1996&amp;author=Zweiman%2CB&amp;author=Valenzano%2CM&amp;author=Atkins%2CPC&amp;author=Tanus%2CT&amp;author=Getsy%2CJA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Sabroe, R. A. et al. Classification of anti-FcϵRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. <i>J. Allergy Clin. Immunol.</i> <b>110</b>, 492–499 (2002).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1067%2Fmai.2002.126782" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1067/mai.2002.126782" data-track-item_id="10.1067/mai.2002.126782">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38XnvVSru7c%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12209101" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Classification%20of%20anti-Fc%CF%B5RI%20and%20anti-IgE%20autoantibodies%20in%20chronic%20idiopathic%20urticaria%20and%20correlation%20with%20disease%20severity&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1067%2Fmai.2002.126782&amp;volume=110&amp;pages=492-499&amp;publication_year=2002&amp;author=Sabroe%2CRA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Biagtan, M. J., Viswanathan, R. K., Evans, M. D. &amp; Mathur, S. K. Clinical utility of the chronic urticaria index. <i>J. Allergy Clin. Immunol.</i> <b>127</b>, 1626–1627 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2011.01.045" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2011.01.045" data-track-item_id="10.1016/j.jaci.2011.01.045">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21376378" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105218" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20utility%20of%20the%20chronic%20urticaria%20index&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2011.01.045&amp;volume=127&amp;pages=1626-1627&amp;publication_year=2011&amp;author=Biagtan%2CMJ&amp;author=Viswanathan%2CRK&amp;author=Evans%2CMD&amp;author=Mathur%2CSK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Gericke, J. et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. <i>J. Allergy Clin. Immunol.</i> <b>139</b>, 1059–1061.e1 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2016.07.047" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2016.07.047" data-track-item_id="10.1016/j.jaci.2016.07.047">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XitVyjur3L" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27838346" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Serum%20autoreactivity%20predicts%20time%20to%20response%20to%20omalizumab%20therapy%20in%20chronic%20spontaneous%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2016.07.047&amp;volume=139&amp;pages=1059-1061.e1&amp;publication_year=2017&amp;author=Gericke%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Ghazanfar, M. N., Sand, C. &amp; Thomsen, S. F. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. <i>Br. J. Dermatol.</i> <b>175</b>, 404–406 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fbjd.14540" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/bjd.14540" data-track-item_id="10.1111/bjd.14540">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhtlGmsrjE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26972689" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Effectiveness%20and%20safety%20of%20omalizumab%20in%20chronic%20spontaneous%20or%20inducible%20urticaria%3A%20evaluation%20of%20154%20patients&amp;journal=Br.%20J.%20Dermatol.&amp;doi=10.1111%2Fbjd.14540&amp;volume=175&amp;pages=404-406&amp;publication_year=2016&amp;author=Ghazanfar%2CMN&amp;author=Sand%2CC&amp;author=Thomsen%2CSF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Kolkhir, P. et al. Reply. <i>J. Allergy Clin. Immunol.</i> <b>141</b>, 1166–1167 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2017.09.010" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2017.09.010" data-track-item_id="10.1016/j.jaci.2017.09.010">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29102069" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Reply&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2017.09.010&amp;volume=141&amp;pages=1166-1167&amp;publication_year=2018&amp;author=Kolkhir%2CP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">De Swerdt, A. et al. Detection of basophil-activating IgG autoantibodies in chronic idiopathic urticaria by induction of CD 63. <i>J. Allergy Clin. Immunol.</i> <b>116</b>, 662–667 (2005).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2005.04.042" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2005.04.042" data-track-item_id="10.1016/j.jaci.2005.04.042">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtVWhtLfP" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16159640" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Detection%20of%20basophil-activating%20IgG%20autoantibodies%20in%20chronic%20idiopathic%20urticaria%20by%20induction%20of%20CD%2063&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2005.04.042&amp;volume=116&amp;pages=662-667&amp;publication_year=2005&amp;author=De%20Swerdt%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28">Cho, C. B. et al. Autoantibodies in chronic idiopathic urticaria and nonurticarial systemic autoimmune disorders. <i>Ann. Allergy Asthma Immunol.</i> <b>110</b>, 29–33 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.anai.2012.10.020" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.anai.2012.10.020" data-track-item_id="10.1016/j.anai.2012.10.020">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhvVaqu7rJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23244655" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901433" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Autoantibodies%20in%20chronic%20idiopathic%20urticaria%20and%20nonurticarial%20systemic%20autoimmune%20disorders&amp;journal=Ann.%20Allergy%20Asthma%20Immunol.&amp;doi=10.1016%2Fj.anai.2012.10.020&amp;volume=110&amp;pages=29-33&amp;publication_year=2013&amp;author=Cho%2CCB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Hata, D. et al. Involvement of Bruton’s tyrosine kinase in FcεRI-dependent mast cell degranulation and cytokine production. <i>J. Exp. Med.</i> <b>187</b>, 1235–1247 (1998).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1084%2Fjem.187.8.1235" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1084/jem.187.8.1235" data-track-item_id="10.1084/jem.187.8.1235">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1cXis1Cru7k%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9547335" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212237" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Involvement%20of%20Bruton%E2%80%99s%20tyrosine%20kinase%20in%20Fc%CE%B5RI-dependent%20mast%20cell%20degranulation%20and%20cytokine%20production&amp;journal=J.%20Exp.%20Med.&amp;doi=10.1084%2Fjem.187.8.1235&amp;volume=187&amp;pages=1235-1247&amp;publication_year=1998&amp;author=Hata%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Kneidinger, M. et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. <i>Blood</i> <b>111</b>, 3097–3107 (2008).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2007-08-104372" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2007-08-104372" data-track-item_id="10.1182/blood-2007-08-104372">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXjvVamtLY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18180381" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20effects%20of%20dasatinib%20on%20IgE%20receptor-dependent%20activation%20and%20histamine%20release%20in%20human%20basophils&amp;journal=Blood&amp;doi=10.1182%2Fblood-2007-08-104372&amp;volume=111&amp;pages=3097-3107&amp;publication_year=2008&amp;author=Kneidinger%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Regan, J. A. et al. Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. <i>J. Allergy Clin. Immunol.</i> <b>140</b>, 875–879.e1 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2017.03.013" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2017.03.013" data-track-item_id="10.1016/j.jaci.2017.03.013">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXms12rtL0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28389390" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366359" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Ibrutinib%2C%20a%20Bruton%E2%80%99s%20tyrosine%20kinase%20inhibitor%20used%20for%20treatment%20of%20lymphoproliferative%20disorders%2C%20eliminates%20both%20aeroallergen%20skin%20test%20and%20basophil%20activation%20test%20reactivity&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2017.03.013&amp;volume=140&amp;pages=875-879.e1&amp;publication_year=2017&amp;author=Regan%2CJA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">Dispenza, M. C. et al. Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy. <i>J. Allergy Clin. Immunol.</i> <b>141</b>, 1914–1916.e7 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2017.12.987" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2017.12.987" data-track-item_id="10.1016/j.jaci.2017.12.987">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29360526" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297295" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Short-term%20ibrutinib%20therapy%20suppresses%20skin%20test%20responses%20and%20eliminates%20IgE-mediated%20basophil%20activation%20in%20adults%20with%20peanut%20or%20tree%20nut%20allergy&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2017.12.987&amp;volume=141&amp;pages=1914-1916.e7&amp;publication_year=2018&amp;author=Dispenza%2CMC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Herman, A. E. et al. Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton’s tyrosine kinase inhibitor. <i>Clin. Pharmacol. Ther.</i> <b>103</b>, 1020–1028 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2Fcpt.1056" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/cpt.1056" data-track-item_id="10.1002/cpt.1056">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtVOqsrrK" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29484638" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20pharmacokinetics%2C%20and%20pharmacodynamics%20in%20healthy%20volunteers%20treated%20with%20GDC-0853%2C%20a%20selective%20reversible%20Bruton%E2%80%99s%20tyrosine%20kinase%20inhibitor&amp;journal=Clin.%20Pharmacol.%20Ther.&amp;doi=10.1002%2Fcpt.1056&amp;volume=103&amp;pages=1020-1028&amp;publication_year=2018&amp;author=Herman%2CAE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Isenberg, D. et al. Efficacy, safety, and pharmacodynamic effects of Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. <i>Arthritis Rheumatol</i>. <a href="https://doi.org/10.1002/art.41811" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1002/art.41811">https://doi.org/10.1002/art.41811</a> (2021).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Cohen, S. et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study). <i>Arthritis Rheumatol.</i> <b>72</b>, 1435–1446 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2Fart.41275" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/art.41275" data-track-item_id="10.1002/art.41275">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslGitLjM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496340" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Fenebrutinib%20versus%20placebo%20or%20adalimumab%20in%20rheumatoid%20arthritis%3A%20a%20randomized%2C%20double-blind%2C%20phase%20II%20trial%20%28ANDES%20study%29&amp;journal=Arthritis%20Rheumatol.&amp;doi=10.1002%2Fart.41275&amp;volume=72&amp;pages=1435-1446&amp;publication_year=2020&amp;author=Cohen%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Ertas, R., Ozyurt, K., Atasoy, M., Hawro, T. &amp; Maurer, M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. <i>Allergy</i> <b>73</b>, 705–712 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fall.13345" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/all.13345" data-track-item_id="10.1111/all.13345">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXjtlOqsbw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29083482" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20clinical%20response%20to%20omalizumab%20in%20chronic%20spontaneous%20urticaria%20patients%20is%20linked%20to%20and%20predicted%20by%20IgE%20levels%20and%20their%20change&amp;journal=Allergy&amp;doi=10.1111%2Fall.13345&amp;volume=73&amp;pages=705-712&amp;publication_year=2018&amp;author=Ertas%2CR&amp;author=Ozyurt%2CK&amp;author=Atasoy%2CM&amp;author=Hawro%2CT&amp;author=Maurer%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Soundararajan, S., Kikuchi, Y., Joseph, K. &amp; Kaplan, A. P. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. <i>J. Allergy Clin. Immunol.</i> <b>115</b>, 815–821 (2005).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2004.12.1120" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2004.12.1120" data-track-item_id="10.1016/j.jaci.2004.12.1120">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXivV2is74%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15806004" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Functional%20assessment%20of%20pathogenic%20IgG%20subclasses%20in%20chronic%20autoimmune%20urticaria&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2004.12.1120&amp;volume=115&amp;pages=815-821&amp;publication_year=2005&amp;author=Soundararajan%2CS&amp;author=Kikuchi%2CY&amp;author=Joseph%2CK&amp;author=Kaplan%2CAP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38"><i>Guidance for industry. Drug-induced Liver Injury: Premarketing Clinical Evaluation.</i> Drug Safety (U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, 2009); <a href="https://www.fda.gov/media/116737/download" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="https://www.fda.gov/media/116737/download">https://www.fda.gov/media/116737/download</a></p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Dispenza, M. C. et al. Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. <i>J. Clin. Invest.</i> <b>130</b>, 4759–4770 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1172%2FJCI138448" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1172/JCI138448" data-track-item_id="10.1172/JCI138448">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvVejtrjJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32484802" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456252" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Bruton%E2%80%99s%20tyrosine%20kinase%20inhibition%20effectively%20protects%20against%20human%20IgE-mediated%20anaphylaxis&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI138448&amp;volume=130&amp;pages=4759-4770&amp;publication_year=2020&amp;author=Dispenza%2CMC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Crawford, J. J. et al. Discovery of GDC-0853: a potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development. <i>J. Med. Chem.</i> <b>61</b>, 2227–2245 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1021%2Facs.jmedchem.7b01712" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1021/acs.jmedchem.7b01712" data-track-item_id="10.1021/acs.jmedchem.7b01712">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXivFCnt7c%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29457982" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Discovery%20of%20GDC-0853%3A%20a%20potent%2C%20selective%2C%20and%20noncovalent%20Bruton%E2%80%99s%20tyrosine%20kinase%20inhibitor%20in%20early%20clinical%20development&amp;journal=J.%20Med.%20Chem.&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;volume=61&amp;pages=2227-2245&amp;publication_year=2018&amp;author=Crawford%2CJJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR41">Deza, G. et al. Relevance of the basophil high-affinity IgE receptor in chronic urticaria: clinical experience from a tertiary care institution. <i>J. Allergy Clin. Immunol. Pract.</i> <b>7</b>, 1619–1626.e1 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaip.2019.01.026" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaip.2019.01.026" data-track-item_id="10.1016/j.jaip.2019.01.026">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30685572" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Relevance%20of%20the%20basophil%20high-affinity%20IgE%20receptor%20in%20chronic%20urticaria%3A%20clinical%20experience%20from%20a%20tertiary%20care%20institution&amp;journal=J.%20Allergy%20Clin.%20Immunol.%20Pract.&amp;doi=10.1016%2Fj.jaip.2019.01.026&amp;volume=7&amp;pages=1619-1626.e1&amp;publication_year=2019&amp;author=Deza%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR42">Holowka, D., Sil, D., Torigoe, C. &amp; Baird, B. Insights into immunoglobulin E receptor signaling from structurally defined ligands. <i>Immunol. Rev.</i> <b>217</b>, 269–279 (2007).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fj.1600-065X.2007.00517.x" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/j.1600-065X.2007.00517.x" data-track-item_id="10.1111/j.1600-065X.2007.00517.x">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXnt1Gmu7w%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17498065" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Insights%20into%20immunoglobulin%20E%20receptor%20signaling%20from%20structurally%20defined%20ligands&amp;journal=Immunol.%20Rev.&amp;doi=10.1111%2Fj.1600-065X.2007.00517.x&amp;volume=217&amp;pages=269-279&amp;publication_year=2007&amp;author=Holowka%2CD&amp;author=Sil%2CD&amp;author=Torigoe%2CC&amp;author=Baird%2CB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR43">Vonakis, B. M. &amp; Saini, S. S. Syk-deficient basophils from donors with chronic idiopathic urticaria exhibit a spectrum of releasability. <i>J. Allergy Clin. Immunol.</i> <b>121</b>, 262–264 (2008).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2007.10.010" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2007.10.010" data-track-item_id="10.1016/j.jaci.2007.10.010">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXovVyqug%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18206515" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Syk-deficient%20basophils%20from%20donors%20with%20chronic%20idiopathic%20urticaria%20exhibit%20a%20spectrum%20of%20releasability&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2007.10.010&amp;volume=121&amp;pages=262-264&amp;publication_year=2008&amp;author=Vonakis%2CBM&amp;author=Saini%2CSS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR44">Puccetti, A. et al. In chronic idiopathic urticaria autoantibodies against FcɛRII/CD23 induce histamine release via eosinophil activation. <i>Clin. Exp. Allergy</i> <b>35</b>, 1599–1607 (2005).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fj.1365-2222.2005.02380.x" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/j.1365-2222.2005.02380.x" data-track-item_id="10.1111/j.1365-2222.2005.02380.x">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28Xnt12rtw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16393326" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=In%20chronic%20idiopathic%20urticaria%20autoantibodies%20against%20Fc%C9%9BRII%2FCD23%20induce%20histamine%20release%20via%20eosinophil%20activation&amp;journal=Clin.%20Exp.%20Allergy&amp;doi=10.1111%2Fj.1365-2222.2005.02380.x&amp;volume=35&amp;pages=1599-1607&amp;publication_year=2005&amp;author=Puccetti%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR45">Griffith, Q. K., Liang, Y., Onguru, D. O., Mwinzi, P. N. &amp; Ganley-Leal, L. M. CD23-bound IgE augments and dominates recall responses through human naive B cells. <i>J. Immunol.</i> <b>186</b>, 1060–1067 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4049%2Fjimmunol.1002709" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4049/jimmunol.1002709" data-track-item_id="10.4049/jimmunol.1002709">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXjs1Kruw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21160045" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD23-bound%20IgE%20augments%20and%20dominates%20recall%20responses%20through%20human%20naive%20B%20cells&amp;journal=J.%20Immunol.&amp;doi=10.4049%2Fjimmunol.1002709&amp;volume=186&amp;pages=1060-1067&amp;publication_year=2011&amp;author=Griffith%2CQK&amp;author=Liang%2CY&amp;author=Onguru%2CDO&amp;author=Mwinzi%2CPN&amp;author=Ganley-Leal%2CLM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR46">Amanna, I. J., Carlson, N. E. &amp; Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. <i>N. Engl. J. Med.</i> <b>357</b>, 1903–1915 (2007).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa066092" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa066092" data-track-item_id="10.1056/NEJMoa066092">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXht1ymtbjI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17989383" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Duration%20of%20humoral%20immunity%20to%20common%20viral%20and%20vaccine%20antigens&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa066092&amp;volume=357&amp;pages=1903-1915&amp;publication_year=2007&amp;author=Amanna%2CIJ&amp;author=Carlson%2CNE&amp;author=Slifka%2CMK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR47">Hibi, T. &amp; Dosch, H. M. Limiting dilution analysis of the B cell compartment in human bone marrow. <i>Eur. J. Immunol.</i> <b>16</b>, 139–145 (1986).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2Feji.1830160206" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/eji.1830160206" data-track-item_id="10.1002/eji.1830160206">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DyaL287msVGlsA%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2869953" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Limiting%20dilution%20analysis%20of%20the%20B%20cell%20compartment%20in%20human%20bone%20marrow&amp;journal=Eur.%20J.%20Immunol.&amp;doi=10.1002%2Feji.1830160206&amp;volume=16&amp;pages=139-145&amp;publication_year=1986&amp;author=Hibi%2CT&amp;author=Dosch%2CHM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR48">Smith, C. I. et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. <i>J. Immunol.</i> <b>152</b>, 557–565 (1994).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4049%2Fjimmunol.152.2.557" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4049/jimmunol.152.2.557" data-track-item_id="10.4049/jimmunol.152.2.557">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK2cXhtVCrsb0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8283037" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Expression%20of%20Bruton%E2%80%99s%20agammaglobulinemia%20tyrosine%20kinase%20gene%2C%20BTK%2C%20is%20selectively%20down-regulated%20in%20T%20lymphocytes%20and%20plasma%20cells&amp;journal=J.%20Immunol.&amp;doi=10.4049%2Fjimmunol.152.2.557&amp;volume=152&amp;pages=557-565&amp;publication_year=1994&amp;author=Smith%2CCI" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR49">Katewa, A. et al. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis. <i>JCI Insight</i> <b>2</b>, e90111 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1172%2Fjci.insight.90111" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1172/jci.insight.90111" data-track-item_id="10.1172/jci.insight.90111">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28405610" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374071" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Btk-specific%20inhibition%20blocks%20pathogenic%20plasma%20cell%20signatures%20and%20myeloid%20cell-associated%20damage%20in%20IFN%CE%B1-driven%20lupus%20nephritis&amp;journal=JCI%20Insight&amp;doi=10.1172%2Fjci.insight.90111&amp;volume=2&amp;publication_year=2017&amp;author=Katewa%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR50">Montalban, X. et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. <i>N. Engl. J. Med.</i> <b>380</b>, 2406–2417 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1901981" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1901981" data-track-item_id="10.1056/NEJMoa1901981">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXnsFGqurs%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31075187" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Placebo-controlled%20trial%20of%20an%20oral%20BTK%20inhibitor%20in%20multiple%20sclerosis&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1901981&amp;volume=380&amp;pages=2406-2417&amp;publication_year=2019&amp;author=Montalban%2CX" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR51">Atallah, E. et al. Zanubrutinib-induced liver injury: a case report and literature review. <i>BMC Gastroenterol.</i> <b>21</b>, 244 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s12876-021-01825-2" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s12876-021-01825-2" data-track-item_id="10.1186/s12876-021-01825-2">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34051727" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164809" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Zanubrutinib-induced%20liver%20injury%3A%20a%20case%20report%20and%20literature%20review&amp;journal=BMC%20Gastroenterol.&amp;doi=10.1186%2Fs12876-021-01825-2&amp;volume=21&amp;publication_year=2021&amp;author=Atallah%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR52">Kaplan, A. et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. <i>J. Allergy Clin. Immunol.</i> <b>132</b>, 101–109 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jaci.2013.05.013" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jaci.2013.05.013" data-track-item_id="10.1016/j.jaci.2013.05.013">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtVWlsbzF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23810097" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Omalizumab%20in%20patients%20with%20symptomatic%20chronic%20idiopathic%2Fspontaneous%20urticaria%20despite%20standard%20combination%20therapy&amp;journal=J.%20Allergy%20Clin.%20Immunol.&amp;doi=10.1016%2Fj.jaci.2013.05.013&amp;volume=132&amp;pages=101-109&amp;publication_year=2013&amp;author=Kaplan%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR53">Maurer, M. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. <i>N. Engl. J. Med.</i> <b>368</b>, 924–935 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1215372" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1215372" data-track-item_id="10.1056/NEJMoa1215372">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXjvFChsrk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23432142" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Omalizumab%20for%20the%20treatment%20of%20chronic%20idiopathic%20or%20spontaneous%20urticaria&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1215372&amp;volume=368&amp;pages=924-935&amp;publication_year=2013&amp;author=Maurer%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR54">Saini, S. S. et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H<sub>1</sub> antihistamines: a randomized, placebo-controlled study. <i>J. Invest. Dermatol.</i> <b>135</b>, 67–75 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fjid.2014.306" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/jid.2014.306" data-track-item_id="10.1038/jid.2014.306">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25046337" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20and%20safety%20of%20omalizumab%20in%20patients%20with%20chronic%20idiopathic%2Fspontaneous%20urticaria%20who%20remain%20symptomatic%20on%20H1%20antihistamines%3A%20a%20randomized%2C%20placebo-controlled%20study&amp;journal=J.%20Invest.%20Dermatol.&amp;doi=10.1038%2Fjid.2014.306&amp;volume=135&amp;pages=67-75&amp;publication_year=2015&amp;author=Saini%2CSS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR55">Kulthanan, K. et al. Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). <i>Health Qual. Life Outcomes</i> <b>14</b>, 61 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s12955-016-0466-y" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s12955-016-0466-y" data-track-item_id="10.1186/s12955-016-0466-y">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27075142" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831163" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Validity%2C%20reliability%20and%20interpretability%20of%20the%20Thai%20version%20of%20the%20urticaria%20control%20test%20%28UCT%29&amp;journal=Health%20Qual.%20Life%20Outcomes&amp;doi=10.1186%2Fs12955-016-0466-y&amp;volume=14&amp;publication_year=2016&amp;author=Kulthanan%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR56">Mathias, S. D., Crosby, R. D., Zazzali, J. L., Maurer, M. &amp; Saini, S. S. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. <i>Ann. Allergy Asthma Immunol.</i> <b>108</b>, 20–24 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.anai.2011.09.008" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.anai.2011.09.008" data-track-item_id="10.1016/j.anai.2011.09.008">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22192960" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Evaluating%20the%20minimally%20important%20difference%20of%20the%20urticaria%20activity%20score%20and%20other%20measures%20of%20disease%20activity%20in%20patients%20with%20chronic%20idiopathic%20urticaria&amp;journal=Ann.%20Allergy%20Asthma%20Immunol.&amp;doi=10.1016%2Fj.anai.2011.09.008&amp;volume=108&amp;pages=20-24&amp;publication_year=2012&amp;author=Mathias%2CSD&amp;author=Crosby%2CRD&amp;author=Zazzali%2CJL&amp;author=Maurer%2CM&amp;author=Saini%2CSS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR57">O’Kelly, M. &amp; Ratitch, B. <i>Clinical Trials with Missing Data: a Guide for Practitioners</i> (John Wiley &amp; Sons, 2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2F9781118762516" data-track="click_references" data-track-action="book reference" data-track-value="book reference" data-track-label="10.1002/9781118762516" data-track-item_id="10.1002/9781118762516">Book</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20Trials%20with%20Missing%20Data%3A%20a%20Guide%20for%20Practitioners&amp;doi=10.1002%2F9781118762516&amp;publication_year=2014&amp;author=O%E2%80%99Kelly%2CM&amp;author=Ratitch%2CB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    

    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif " data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: Flagship">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Flagship">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing" src="/static/images/logos/nature-briefing-logo-n150-white-d81c9da3ec.svg" width="250" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing</em> newsletter — what matters in science, free to your inbox daily.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/briefing" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: Flagship">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="MainBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="MainBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:nature_briefing_daily" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Flagship">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get the most important science stories of the day, free in your inbox.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="https://www.nature.com/briefing/signup/?brieferEntryPoint=MainBriefingBanner">Sign up for Nature Briefing
            </a>
        </div>

    </div>

</div>






<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-021-01537-w&amp;format=js&amp;last_modified=2021-11-08" async=""></script>

<act-dvpqipzicojg></act-dvpqipzicojg><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>